## we are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists



122,000

135M



Our authors are among the

TOP 1%





WEB OF SCIENCE

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

### Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com



Gloria Esteso, Ángeles Jiménez-Marín, Gema Sanz, Juan José Garrido and Manuel Barbancho Unidad de Genómica y Mejora Animal, Departamento de Genética, Universidad de Córdoba Spain

#### 1. Introduction

Integrins are a long family of heterodimeric transmembrane glycoproteins consisting of multiple combinations of noncovalently linked  $\alpha$  and  $\beta$  chains, which generate different complex receptors with different expression patterns and ligand binding profiles. The integrins bind to extracellular matrix (ECM) or to cell-surface ligands, regulating numerous downstream pathways (Hynes, 2002).

Each integrin binds to only a limited series of ligands, ensuring that cell adhesion and migration are precisely regulated. The  $\alpha$  subunit mainly determines the substrate specificity with extracellular matrix molecules (ECM) (Yamada, 1991), while the intracytoplasmic tail of the  $\beta$  chain is predominantly responsible for the integrin interaction with the cell cytoskeleton by binding to vinculin, talin and  $\alpha$ -actin (Isenberg, 1991). Thus, this heterodimeric association between  $\alpha$  and  $\beta$  subunits allows the integrins to act as bidirectional signaling molecules in the different tissues and cell types in which they are widely distributed, mediating a variety of biological processes so diverse as embryogenesis, haemostasis, tissue repair, migration, cell polarity, immune response and metastatic diffusion of tumor cells (Hynes, 1987, 1992; Hemler et al., 1994).

Mammalian integrins have been divided into subfamilies according to their  $\beta$  subunit. The most important  $\beta$  integrin subfamilies are  $\beta_1$ ,  $\beta_2$  and  $\beta_3$ . Within a subfamily, the same  $\beta$  subunit can associate with different  $\alpha$  subunits. To date, 18  $\alpha$  and 8  $\beta$  chains -whose combinations provide up to 24 different integrins- have been described in mammal species (Hynes et al., 2002; Alam et al, 2007).

<sup>&</sup>lt;sup>1</sup>The experiments and results showed in this chapter belong to the PhD by G. Esteso directed by J.J. Garrido.

 $<sup>^2</sup>$ Sequence data from this article has been deposited with the GenBank Data Libraries under Accession  $N^{\rm o}$  JF808665.

The  $\alpha_{IIb}$  chain only associates with the  $\beta_3$  chain providing the  $\alpha_{IIb}\beta_3$  (CD41/CD61) integrin receptor which is the most abundant one in platelets. The main role of the  $\alpha_{IIb}\beta_3$  receptor is the binding of fibrinogen to the surface of the activated platelet, thereby resulting in the platelet aggregation with significant consequences in the thrombosis and the homeostasis attainment (Clark & Brugge, 1995; Schwartz et al., 1995). Although for a long time it was thought that the  $\alpha_{IIb}$  integrin expression was limited to platelets and their precursors (the megakaryocytes), several studies have revealed that the  $\alpha_{IIb}$  chains are also expressed in myeloid and in hematopoietic cells (Ody et al., 1999; Corbel and Salaun, 2002). In addition,  $\alpha_{IIb}\beta_3$  integrin plays an important role in the progression and invasion of tumors (Chen et al., 1992; 1997) and in the differentiation of cells from the myeloid lineage in bone marrow (Chen et al, 1997; Wall et al, 1997). In humans, both subunits of the  $\alpha_{IIb}\beta_3$  integrin show a high level of polymorphism resulting in some cases in clinically important hemorrhagic disorders (Weiss et al., 1996).

Consequently,  $\alpha_{IIb}$  has been involved in many, different and important functions related with platelet activation and tumor progression. However, most studies related to  $\alpha_{IIb}$ integrin have been carried out in humans, and little is known about the expression of  $\alpha_{IIb}$ subunit in porcine tissues and cell types, although pig is generally accepted as an optimal experimental model which is used in different areas as immunology, xenotransplantation, artherosclerosis, cancer or cardiovascular disease because of its similarity to humans (Misdorp, 2003; Lunney, 2007).

In the present study we describe the cloning and molecular characterization of a cDNA encoding the porcine  $\alpha_{IIb}$  (CD41) integrin, and the expression pattern of the  $\alpha_{IIb}$  mRNAs in a variety of porcine cells and tissues. In parallel, we use immunohistochemistry and flow cytometry to accurately locate the porcine  $\alpha_{IIb}$  integrin protein in the same tissues and cell types. For this, we produce a monoclonal antibody against a porcine recombinant  $\alpha_{IIb}$  protein. We also study if any change is produced in the level of  $\alpha_{IIb}$  transcripts in thrombin stimulated platelets. Additionally, we identify the chromosomal localization of the porcine *CD41* gene.

#### 2. Material and methods

#### 2.1 Tissues and cells

Fresh pig blood from approximately 1 year old healthy pigs was collected at the slaughterhouse into sodium citrate to final concentration of 10% v/v of the anticoagulant. Platelets isolation was carried out according to García et al., 2005. Porcine platelets were pelleted from plateled-rich plasma (PRP) obtained by centrifugation at 200g for 20 min of blood after addition of ACD solution (117mMsodium citrate, 282mMglucose and 78mMcitric acid) to a concentration of 7%v/v. The upper third of the PRP was centrifuged again after addition of prostacyclin (final concentration 2.5 mM) to avoid platelets activation. For platelets activation, the cells were stimulated by the addition of 1 U of thrombin for 3min at 37°C. Porcine tissues were recovered from adult pigs immediately after slaughtering at the local abattoir and frozen in liquid nitrogen until use. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized whole blood using Ficoll-Hypaque (density 1077 g/ml, Sigma) centrifugation at 900 g for 30 min. Mononuclear cells (lymphocytes and monocytes) and granulocytes were collected by aspiration from their respective gradient interphases and washed twice in PBS.

#### 2.2 RNA isolation, RT-PCR and RACE

Total RNA from platelets, cells or tissues was purified according to the M-MLV Reverse *Transcriptase system* (Invitrogene) using the random primers pd(N)<sub>6</sub>-5'-PO<sub>3</sub>NA+Salt (Pharmacia Biotech). RNA samples were kept at -80°C after controlling the quality on a denaturing agarose gel. 5 µg RNA, resuspended in 9.5 µl water, were heated for 3 min at 65°C in the presence of random hexamers (7.5 µM final concentration), and then cooled in ice. RNA was reverse transcribed using 1 µl Moloney murine leukemia virus reverse transcriptase (200 units/µl) (GibcoBRL) for 1 h at 42°C in a final volume of 20 µl containing 4 µl of 5X reverse transcriptase buffer, 0,5 µl ribonuclease inhibitor (50 U/µl) (Roche), 1 µl 20 mM dNTP (Pharmacia) and 2  $\mu$ l 0.1 M dithiothreitol. After 10 min at room temperature, 1 h at 42 ° C, and 10 min at 95°C, DEPC H<sub>2</sub>O were added until a final volume of 100  $\mu$ l. 2  $\mu$ l of this mixture were subjected to PCR using 1µl Tth DNA polymerase (1U/µl) (Biotools) and 2,5 µl each CD41specific primer (20µM) (see Table 1) in a final volume of 50 µl containing 5 µl 10x buffer, 2 µl MgCl<sub>2</sub> (50 mM), and 8 µl dNTP MIX (1,25 mM each) (Biotools). The amplification consisted in 35 cycles of PCR and each cycle consisted of incubations at 94°C for 1 min, Tm°C for 1 min, and 72°C for 1 min. The amplifications were electrophoresed on 1% agarose/1X TAE gel. RT-PCR on RNA18S cDNA was used as a control. For RACE (Rapid Amplification of cDNA Ends), 1 µg total RNA from platelet was used to reverse-transcribe using 1 µl Moloney murine leukemia virus reverse transcriptase (200 units/µl) (GibcoBRL) for 1 h at 42°C in a final volume of 20 µl containing 4 µl of 10X reverse transcriptase buffer, 1,0 µl ribonuclease inhibitor (50  $U/\mu$ l) (Roche), 4  $\mu$ l 2,5 mM dNTP (Pharmacia) and 2  $\mu$ l 3' RACE ADAPTER (20  $\mu$ M) in a final volume of 20 µL. 3' CD41 cDNAs were obtained by PCR using a specific porcine CD41 primer and the anchor primer provided in the kit (Table 1).

#### 2.3 DNA sequencing and sequences analysis

Sequencing was performed using ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) on a thermal DNA cycler GeneAmp PCR System 2400 (Applied Biosystems, Foster City, CA, USA), according to the instructions of the manufacturer, and analysed on an ABI PRISM 3100 Sequencer (Applied Biosystems, Foster City, CA, USA). Porcine CD41 sequence has been deposited at GenBank under number JF808665. Sequences were analyzed using the analysis software LaserGene (DNAstar, Londo, UK) and the analysis tools provided by the expasy web site <http://www.expaxy.org>. Primers design was performed with Oligo 6 (MBI, Cascade, CO, USA) and Amplify 3 (<http://www.engels.genetics.wisc.edu/amplify/>). Multiple alignment among CD41 peptide sequences from Sus scrofa (GenBank accession no. JF808665), Homo sapiens (GenBank accession no. AAI26443), Bos taurus (GenBank accession no. NP\_001014929), Mus musculus (GenBank accession no. NP\_034705), Rattus norvegicus (GenBank accession no. XP001063315), Canis familiaris (GenBank accession no. NP\_001003163), Equs caballus (GenBank accession no. NP\_001075262), Oryctolagus cuniculus (GenBank accession no. Q9TUN4), Danio rerio (GenBank accession no. AAQ82784) and Xenopus laevis (GenBank accession no. Q5XH72) was performed by using MUSCLE program (Edgar, 2004).

#### 2.4 Recombinant CD41 protein (rpCD41) expression and purification

DNAs encoding extracellular domains of the porcine CD41 were amplified by PCR. Primers used for amplification contained restriction sites enabling ligation into the expression vector

*pET28b* (Novagen) following digestion of the PCR product and the vector with *Bam*HI and *Hind*III. Two different pairs of primers were used: F1rp-*Eco*RI/R1r-p*Xho*I and F2rp-*Bam*HI/R2rp-*Hind*III (Table1). PCR product was ligated into the expression vector *pET28b* and used to transform *Escherichia coli* strain *BL21* (*DE3*) (Novagen). Recombinant proteins (rpCD41-F1R1 and rpCD41-F2R2), expression and purification were carried out following previously procedures described by us (Jiménez-Marín et al., 2000).

#### 2.5 Antibodies production

A monoclonal antibody, GE2B6, against rpCD41-F2R2 and two polyclonal antibodies, antirpCD41-F1R1 and anti- rpCD41-F2R2, were produced using previously described immunization and cells fusion procedures (Arce et al., 2002; Jiménez-Marín et al., 2000). Briefly, female BALB/c mice were immunized with 50 µg of rpCD51. Spleen cells from immune mice were fused with Sp2/0 myeloma cells. Hybridoma clones were selected on the basis of binding secreted antibody to rpCD61 by indirect ELISA. Antibody-producing hybridomas reacting positively were cloned at least twice by limiting dilution. Immunoglobulin classes and subclasses were determined in solid-phase ELISA using rabbit antisera specific for mouse heavy and light chains and a peroxidase-conjugated goat antirabbit immunoglobulin (Sigma).

#### 2.6 Electrophoresis and immunoblottings

Platelets ( $10^8$ /sample) were lysated in NP-40 lysis buffer with PMSF 2 mM with vigorous shaking for 1 h at 4°C, and then centrifuged at 12,000 rpm, 20 min. 100 µl supernatant were mixed with 100 µl of sample treatment buffer, and 100 µl were loaded in the gel. Electrophoresis was carried out in 5%-15% gradient polyacrilamide gels. For the 2D electrophoresis, the platelet proteins pellet was resuspended in lyses buffer (7 M urea, 2 M thiourea, 4% CHAPS, 1% DTT, 0,8% ampholytes). Immobilized pH gradient strips (17 cm, 5-8 linear pH gradient, Bio-Rad) were rehydrated with 300 µl (300 µg) of the protein solution for 16 h, and focused in a PROTEAN IEFcell (Bio-Rad). Second dimension was performed on 10% SDS-PAGE. For the immunoblottings, proteins were transferred from gels to PVDF Inmobilon P membranes (Milipore). Membranes were blocked and washed three times in PBS-T, and then incubated with 3 ml antibody or PBS as negative control, overnight at 4°C in shaking. After three washing ups in PBS-T, the membranes were incubated with rabbit anti-immunoglobulin-peroxidase (Sigma). Afterwards, they were washed up three times in PBS-T, and finally reactions were detected with the ECL<sup>TM</sup> detection system (Amersham) following the manufactures instructions.

#### 2.7 Immunoprecipitation of platelet CD41 proteins

Platelets ( $10^8$ /sample) were incubated with 0.4 mg sulfobiotin (Pierce) with gently shaking for 15 min at 4°C, and then centrifuged at 3,000 rpm, 15 min. Pellet was washed three times in PBS, and then resuspended in lyses buffer (500 µl/sample) and PMSF 2 mM. After incubation in dark with vigorous shaking for 1 h at 4°C, it was centrifuged at 13,000 rpm, 20 min, and the supernatant was collected. 50 µl of protein G-Sepharose (Pharmacia) were added per ml of supernatant and incubated with shaking overnight at 4°C, and then centrifuged at 2,000 rpm, 5 min. 500 µl lysate were incubated with 1 ml of the anti-porcine CD41 antibody for 2 h at room temperature. At the same time, when monoclonal antibody was going to be used, to increase its binding ability, the G protein is

112

recovered with an anti-mouse immunoglobulin rabbit serum (Pierce) 1/10 in lyses buffer, for 2 h at room temperature. Then, the G protein is washed three times in lyses buffer, and centrifuged at 2,000 rpm, 2 min. This step was not needed when polyclonal antibodies were used. 50 µl of the antibody recovered G-Sepharose were added to the lysate containing the anti-CD41 antibody and incubated for 1 h at room temperature with shaking, and then centrifuged at 2,000 rpm, 5 min. The supernatant was collected and washed three times in lyses buffer, the first being in buffer and sucrose. Finally, supernatant was subjected to SDS-PAGE in 5%-15% gels in reducing or not reducing conditions. After electrophoresis, the proteins were transferred to PVDF, Inmobilon P membranes, as described before, and, after be blocked, incubated with a solution of Streptavidin-HRP (Amersham) solution 1/500 in PBS for 1 h in dark. Then, membranes were washed three times in PBS-T and revealed with the ECL<sup>TM</sup> detection system (Amersham) following the manufactures instructions.

#### 2.8 Immunohistochemistry

Expression of CD41 protein from healthy animals was studied following previously procedures described by us (Jiménez-Marín et al., 2008) using monoclonal antibody GE2B6 supernatant or polyclonal antibodies (1/3000 dilution in PBS) or an irrelevant mAb (as negative control). Briefly, all tissue specimens were fixed in Bouin liquid for 16 hours. Tissues were dehydrated in ascending concentrations of ethanol and xylene and embedded in paraffin. Sections of 5 µm were placed on slides coated with Vectabound (Vector Laboratiores, Inc.). The tissue slides were kept at 55°C for 45 min to improve the adherence of sections to glass. The sections were deparaffinized and rehydrated in xylene and descending concentrations of ethanol, respectively. Endogenous peroxidase activity was inhibited with 3% hydrogen peroxidase. The sections were incubated with normal goat serum (1:10 dilution in PBS) (Vector) for 30 min at room temperature. After removing the serum, anti-porcine CD41 antibodies or an irrelevant mAb (as negative control) were added for 18 hours at 4°C in a wet chamber. The sections were incubated with biotinylated antimouse Ig (Dako) diluted 1/50 in PBS for 30 min at room temperature. Tissue sections were covered with avidin-biotin-peroxidase complex (Sigma) diluted 1/50 with PBS for 1 h in a wet chamber at room temperature, washed and then developed with 3, 3'-diaminobenzidine (Sigma) (5 µg in 10 ml PBS). Sections were counterstained with Mayer hematoxylin and mounted with Eukitt.

#### 2.9 Flow cytometry

100  $\mu$ l of platelets (10<sup>6</sup> cells/ml) and 100  $\mu$ l of the antibody (or PBS as a control) were incubated 30 min at 4°C. After washing with PBS, tubes were centrifuged at 3,000 rpm, 6 min, and the platelets resuspended in 50  $\mu$ l of a rabbit FITC-anti-immunoglobulin (1/160 in PBS) (Sigma). After incubation at 4°C 30 min in dark, the platelets were washed three times in PBS and the fixed in 1% PFA/PBS. Samples were analyzed in a FACsort cytometer (Bencton Dickinson) equipped with a CellQuest v 1.2software.

#### 2.10 Chromosome localization

The INRA somatic cell hybrid panel (Yerle et al., 1996) was screened with porcine primers (VARP1 and VARP2), which specifically amplify a 212 bp fragment (Table 1). For genotyping of the hybrid panel, 10 ng of DNA from each cell line and control sample (pig,

hamster, and mouse) were amplified. PCR products were evaluated on a 1% agarose gel and individual cell lines were evaluated for the presence or absence of a fragment of the correct size. Statistical calculations of the assignment were performed using the software developed by Chevalet et al (1997) (<http://www.inra.toulouse.fr>). The INRA-Minesota porcine radiation hybrid (IMpRH) panel (Yerle et al., 1998; Hawken et al., 1999) was screened with the same porcine specific primers in the same PCR conditions (Table 1). Statistical calculations of the assignment were performed using the IMpRH mapping tools (<http://www.imprh.toulouse.inra.fr>).

#### 2.11 Quantitave real time RT-PCR

CD41 cDNA was quantified by real time quantitative PCR (RT-Q-PCR) relative to  $\beta$ actin cDNA reverse transcribed from total RNA from platelets. The PCR reaction was carried out with 0.5 µl of each VARP1/VARP2 and  $\beta$ -actinF/  $\beta$ -actinR primers (Table 1) (20µM), 12.5 µl of iQ<sup>TM</sup> SYBR1 Green Supermix (Bio-Rad), and 1.5 µl of the cDNA sample. The PCR conditions included 40 cycles of 30s at 94°C, 30s at 60°C and 30s at 72°C. All experiments were performed three times to confirm accuracy and reproducibility of real-time PCR. The efficiency of the primers (E) was calculated according to the equation (1).

$$E = 10[-1/p]$$
 (1)

being p the slope of the standard curve log(fluorescence)/Ct.

The relative abundance of CD41 gene expression was determined by the ratio (R) equation (2)

$$R=2^{[\Delta Ct (target)-\Delta Ct (control)]}$$
(2)

being Ct = threshold cycle (cycle at with PCR amplification reaches a significant value).

#### 3. Results

#### 3.1 Cloning and sequence analysis of the porcine CD41 cDNA

The porcine full length *CD41* cDNA was obtained by a combination of PCR and RACE (Rapid Amplification of cDNA Extremes). A partial sequence that lacked the 3' cDNA extreme, including part of the coding sequence, was deposited in GenBank (**AF170526**). So, we first amplified the pig *CD41* 5' cDNA using forward and reverse primers designed from this sequence. Three pairs of primers were used P3/R4, P1/R2 and F1/R1 (Table1).

Three 1352, 870 and 677 bp long overlapping fragments were produced, respectively. Altogether, the three fragments provided a 2701 bp long sequence that belongs to the 5' extreme of the *CD41* cDNA (Figure1). To obtain the remaining 3' sequence of the *CD41* cDNA we carried out a RACE by using the RACE-out and the RACE-P5 primers shown in Table1. This allowed us to obtain an additional 622 bp long 3' sequence (Figure1). Finally, we obtained the full length *CD41* cDNA molecule amplifying RNA from platelets by RT-PCR by using the FcDNA5 and RcDNA3 pair of primers (Table1 and Figure1) and MBLong polimerase.

114

Primers	Primer sequences 5'- 3'	Template, localization (5'-5')	Product size (bp)	Tm (°C)	
FP3 RP4	TGTGGAAGAAGGAAGATGG GCAGAGCCTGCGGCAAAGG	cDNA, 2-1353	1352	58.1	
FP1 RP2	GGGCCAAGTATCGGTGTTC TGGGTACAGATGAGCCTCTCTAAG	cDNA, 1264-2133	870	60.0	
F1 R1	CCCCAGGTGCTCACTACA	cDNA, 2066- 2742	677	60.0	
RACE-adapter	GCGAGCACAGAATTAATACGACTCACT ATAGGT12				
RACE-outer RACE-P5	GCGAGCACAGAATTAATACGACT CTCCCCTGTGTACCCAGCTCATCA	cDNA, 2638-3'	622	60.0	
FcDNA5	CCTAAGCTTAAGATGGCCAGAGCTTTGT GT	cDNA, 13-3125	3113	59.2	
RcDNA3	GCAAAGCTTTCACTCCTCCTCTTCATCA GA				
VARP1 VARP2	GAGGCATGACCTCTTGGTGG CATTGTAGCCATCCCGGTTC	Genomic DNA cDNA, 1012-1223	212	59.0	
F1rp-EcoRI	CGAC <u>GAATTC</u> CCCCAGGTGCTCACTAC A	cDNA, 2066- 2742	677+20	60.0	
R1rp-XhoI	CGA <u>CTCGAG</u> GCAGCTCAGGAGAATTGG A		577+20		
F2rp-BamHI	GGTC <u>GGATCC</u> TTGAACCTGGACCCAGT GCAT	cDNA, 110-1105	996+20	59.0	
R2rp-HindIII	GGT <u>AAGCTT</u> CTGCAGGAACAAGTAAAC ACG	CDINA, 110-1103	290 · 20	59.0	

Table 1. Primers used in PCRs and RACE.




Fig. 1. Strategy and localization of the primers used for cloning the porcine full length *CD41* cDNA.

The full *CD41* cDNA was 3336 bp long and contained an open reading frame of 3111 bp (Figure2) which encodes a CD41 polypeptide of 1036 amino acid residues, and a 198-bp long untranslated 3' flanking region. The nucleotide sequence encoding the full length CD41 pig cDNA was submitted to GenBank (Accession number JF808665).

The first 31 amino acid residues of CD41 are predominantly hydrophobic and correspond to the signal peptide sequence. So, the pig mature pre-CD41 molecule consists of 1005 amino acid residues, and, as this amino acid sequence has a proteolytic cleavage site (KR/D) located between amino acids residues 899 and 900 in pre-CD41 (Takada et al., 1989), the mature porcine CD41 polypeptides –lacking the signal peptide- must be composed by two different chains (914 and 91 amino acid residues) linked by disulfide bridges, similar to those reported in homologous CD41 integrins. Other sequences and structural domains contained in other CD41 proteins are also presents in the porcine CD41 chains (Figure2).

The seven FG-GAP tandem repeats are shown as W with arrows marking their initial and final limits. An  $\alpha$  helix is shown in red. The long extracellular domain of the porcine CD41 integrin consists of 869 amino acids residues. It contains 8 consensus N-glycosylation sites (Asn-X-Ser/Thr, where X is not Pro) identified by the NetNGlyc 1.0 program (www.expasy.org), and 18 -from 19- cystein residues. As in other  $\alpha$  integrins, the extracellular domain of the porcine CD41 contains four Ca<sup>++</sup> binding domains (DX(D/N)XDGXXD) and seven FG-GAP tandem repeats -which are identified by the SABLE 2.0 program (http://sable.cchmc.org/)- each one containing four helixes similar to those previously described (Springer, 1997; Xiong et al., 2001). The secondary structure of CD41 molecule is shown in Figure3 and the tertiary one, obtained with the Swismodel (www.expasy.org), is shown in Figure4.

The stretch sequence of 26 hydrophobic amino acid residues located in the carboxy-terminal portion of the polypeptide must constitute the transmembrane domain. Following it there is a short 20-amino acid sequence that must represent the cytoplasmic domain of the molecule. It contains a GFFKR (1019-1023 in pre-CD41) domain, which is conserved in all human  $\alpha$  integrin chains and is involved in the link of both  $\alpha$  and  $\beta$  chains of the heterodimeric complex (Rojiani et al., 1991). It also contains a  $\beta$ -like turn (PPLEE) (1026-1030), that in comparison to the  $\alpha_v$  chain (PPREE) could aid in the ligand interaction of fibronectin and

vitronectin with the intact  $\alpha_{IIb}\beta_3$  heterodimer which is essential for various transductional processes during mammalian organogenesis (Filardo & Cheresh, 1994).

	TTGTGG.	AAGAAG	GAAG																			_
				м	A F2	R A	. L	С	L	L	H A	L	W	L	L	Е	W	v	Q	L	LI	
GACCCGGTGC	TGCCCC	TCCAAC	CTGG	GCC	-	ACCT	GGAC	CCA	GTG	CAT	TCAC	CATC	TAC	ACA	GGC	cccz	ATC	GC	AGC	CAC	TTTGG	G
G P G A																					FO	
ITTCATTGGA									-										-			
F S L D																						
					0		2	_	•			-			-	-			-	-		-
GCGGCGTTTT								_														
3 G V F	L C	PW	I K	A	ĸ	s v	Q	C	v	A	LS	F	N	L	D	D	Е	т	R	N	ve	3
CCCAAACTTT	CCAAAC	CTTCAF	AGGCC	CGT	CAAG	GACT	AGGG	GCG	TCG	GTCI	TAAC	TTGG	AGA	GAC	AAC	GTTO	TGC	GCC	TGC	GCC	СССТО	G
A Q T F	Q T	F B	C A	R	Q	G L	G	А	s	v	L T	W	R	D	N	v	v	A	C	A	P W	V
	~~~~				~- ~ ~ ~										~ ~ -	~ ~ ~						
AGCACTGGAA O H W N																						
				-	-			-	-		0 0	<u> </u>	-			×	-	×		-		
CGGAGTTCTC																						
AEFS	P C	R A	A N	L	L	S L	v	Y	v	Е	SK	F	N	D	R	R	Y	C	Е	v	GF	2
GCTCTGCGGT	CACTCA	GGCTGC	GGAG	CTG	зтас	TTGG	GGCT	CCT	GGGG	GCT		rTTC	тта	AGT	CTC	ата	CAC	-GG	GCT	CA	ATTGO	C
S S A V																						
	-																					
ATATCATCTC																						
DIIS	SY	RF	'G	т	ь	г м	н	v	P	T.	QK	ь	.т.	B.	D	S	D	ь	Р	ы	X X	2
AGAGCTACTT	GGGGTA	CTCGGI	GGCT	GTG	GGCG	AGTT	CGAC	CGG	ААТ	CCCZ	ACAC	CACA	GAG	TAC	ATC	стсо	GTC	GCC	ccc	ACC	TGGAG	3C
											_											
S S Y L						E F						т									W S	
GACCCTGGG																						
4 T L G	AV	БТ	. в	т	5	КН	Q	R	ь	н	ь ь	Q	G	Е	Q	v	A	S	x	B.	GE	1
CAGTGGCCGT	CACCGA	CGTCA	CGGG	GAC	GGGA	GGCA	TGAC	CTC	TTG	GTGC	GAGC	GCCA	CTG	TAC	ATG	GAG	AGCO	CGT	GCT	GAC	CACAA	٩G
s v a v	тр	v N	I G	D	G	R H	D	- <b>L</b>	<b>L</b> -	V	G A	Р	L	Y	м	Е	s	R	А	D	н к	c
					R	2																_
IGGCCGAGGT																						
	GR	· 1		10		<b>2</b> 5	K	G			5 1	G	1	F	5	-	-		1	G		2
ICTATGGACG	ATTTGG	CTCAGC	CATC	GCG	ССТС	TGGG	CGAC	TTG	AAC	CGGG	ATGG	CTAC	AAT	GAT	GTT	GCC	TG	GCC	GCC	CCC	TATGO	G
YGR	FG	SA	× I	A	P	L G	D	- <b>L</b> -	N	R	D G	Y	N	D	v	A	V	А	A	P	YG	3
TCCCACCGG	P 1	CCAACI	יאירכס	GTC	<b></b>	TCCC	TCAC	ייטעב	GAG	200	ידידים א	סידיר	CAC		TCC	CACO	377.00	ייירכי	CAC		COT	
J P T G																						
	P 4																					
CCGCAGGCTC																		_				
AAGS	A F	GE	r s	ь	R	G A	. т	Б	<u>т</u>	D	D N	G	Y	Р	D	ы.	ы	V	G	A	YG	÷
CCGACAAGGT	TGTCGT	GTACCO	AGCT	CAG	CCGG	TGGT	GACO	GCC	ACTO	GTC	AGCT	GATG	GTG	CAA	GAA	TCCO	TG	AT	CCT	GCT	GTGAA	٩G
АДКУ	vv	Y F	λ	Q	Р	v v	т	A	т	v	Q L	м	v	Q	Е	s	L	N	Р	A	VK	c
																					-	
							here and the		-													
ATTGTGTCCA						_					_											
ATTGTGTCCA						_					_											
ATTGTGTCCA V Q	ΡQ	TR	C T	P	v	s <mark>c</mark>	F	T	I	Q	M C	v	G	A	T	G	н	N	I	P	EK	c
ATTGTGTCCA 1 <mark>C</mark> V Q FGCGCCTAAA	P Q TGCCGA	T R GCTGCA	C T AGCTG	P	V	S C	F	T	I CAG	Q AGCC	M C	V GGTG	G CTG	A CTG	T CTG	G GCT	н гссо	N	I CAG	P GCG	E R	C CT
ATTGTGTCCA I C V Q IGCGCCTAAA L R L N	P Q TGCCGA	T K GCTGCA L Q	C T AGCTG 2 L	P IGACO D	V CGGC R	S C AGAA Q K	F ACCC	T CCAC H	I CAGi Q	Q AGCC S	M C GGCGG R R	V GGTG V	G CTG L	A CTG L	T CTG L	G GCT A	H CCC S	N CAA Q	I CAGO	P GCG2 A	E R AGCAC S I	C T C
ATTGTGTCCA V C V Q IGCGCCTAAA L R L N ICCTGGACGT	P Q TGCCGA A E GGATCT	T R GCTGCA L C GACCTO	G T AGCTG 2 L HGAGG	P GAC D CAG	V CGGC R AGCC	S C AGAA Q K	F ACCC P CTGC	T CCAC H CCAC	I CAG Q AAC	Q AGCC S ACC2		V GGTG V CTTC	G CTG L CTC	A CTG L CGG	T CTG L GAT	G GCT A GAGO	H CCC S SCTC	N CAA Q GAT:		P GCG2 A CGG4	E R AGCAC S I GACAA	CT T
ATTGTGTCCA V C V Q IGCGCCTAAA L R L N ICCTGGACGT	P Q TGCCGA A E GGATCT	T R GCTGCA L C GACCTO	G T AGCTG 2 L HGAGG	P GAC D CAG	V CGGC R AGCC	S C AGAA Q K	F ACCC P CTGC	T CCAC H	I CAG Q AAC	Q AGCC S ACC2	M C GGCGG R R	V GGTG V CTTC	G CTG L CTC	A CTG L CGG	T CTG L GAT	G GCT A GAGO	H CCC S SCTC	N CAA Q GAT:		P GCG2 A CGG4	E R AGCAC S I GACAA	CT T
ATTGTGTCCA V C V Q TGCGCCTAAA L R L N TCCTGGACGT V L D V	P Q TGCCGA A E GGATCT D L		GCTG QL GGAGG VR	P IGACO D ICAGI Q	V CGGC R AGCC S	S C AGAA Q K CCAC P T	F ACCC P CTGC	T CCAC H CCAC H	I CAG2 Q AAC2 N	Q AGCC S ACC2 T	M C CGGCGG R R ACGGCG T A	V GGTG V CTTC F	G CTG L CTC L	A CTG L CGG R	T CTG L GAT D	G GCT: A GAGO E	H TCCC S S CTC A	N Q GAT: D	I Q TTC F	P GCG2 A CGG0 R	E B AGCAC S I GACAA D I	C T L L G K
ATTGTGTCCA V C V Q IGCGCCTAAA L R L N ICCTGGACGT V L D V IGAGCCCCAT	P Q TGCCGA A E GGATCT D L CGTGCT	T B GCTGCA L Q GACCTO T W CAGCTI	T AGCTG D L SGAGG V R TCAAT	P GAC D CAG Q GTG	V CGGC R AGCC S	S C AGAA Q K CCAC P T TGCA	F ACCC P CTGC C GCCC	T CCAC H CCAC H	I CAGi Q AACi N AAGi	Q AGCC S ACCZ T AATC		V GGTG V CTTC F	G CTG L CTC L	A CTG L CGG R ACG	T CTG L GAT D TTC	G GCT: A GAGC E ATGC	H FCCC S GCTC A CTGC	N Q GAT: D CATO	I CAGO Q TTCO F GGAO	P GCG2 A CGG4 R GAC2	E R AGCAC S I GACAA D I ACCCA	C T AG K
ATTGTGTCCA V C V Q IGCGCCTAAA L R L N ICCCTGGACGT V L D V IGAGCCCCAT L S P I	P Q TGCCGA A E GGATCT D L CGTGCT V L	T R GCTGCA L C GACCTO T W CAGCTI S F	C T AGCTG 2 L GGAGG V R FCAAT 7 N	P GAC D CAG Q GTG V	V CGGC R AGCC S TCCC S	S Q CCCAC P T T GCCA L Q	F ACCC P CTGC C GCCC 2 P	T CCAC H CCAC H SGAG E	I Q AAC N AAG	Q AGCC S ACCZ T AATC N	M CGGCGG R R ACGGCG T A GGAGAG G D	V GGTG V CTTC F CGCC A	G CTG L CTC L CTC L	A CTG4 L CGG4 R ACG <sup>2</sup> T	T CTG L GAT D TTC. F	G GCTT A GAGO E ATGO M	H TCCC S GCTC A CTGC L	N Q GAT: D CATO H	I Q TTC F GGA	P BCG3 A CGGC R BAC3 D	E F AGCAC S T GACAA D I ACCCA T I	CT T AG K AC H
TCCTGGACCAT CCCTGGACGT CCCTGGACGT CCCTGGACGT CCCTGGACCAT CCCTGGACCAT CCCTGGACCAT CCCTGGAACA	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG	T R GCTGCA L C GACCTO T W CAGCTI S F CATCAI	T AGCTG L GGAGG V R TCAAT 7 N	P GAC D CAG Q GTG V GAC	V CGGC R AGCC S ICCC S IGTG	S C AGAA Q K CCCAC P T TGCA L Q	F ACCC P CTGC C GCCC P AGAC	T CCAC H CCAC H SGAG E CCAA	I CAGi Q AACi M AAGi K GTG'	Q AGCCZ T AACCZ T AATC N	M C GGCGC R R CGGCGC T A GAGAA G D	V GGTG V CTTC F CGCC A AAAG	G CTG L CTC L CTC L CTC	A CTG4 L CGG4 R ACG <sup>2</sup> T	T CTG L GAT D TTC. F	G GCTT A GAGC E ATGC M	H CCCC S CCCC L SCCC	N Q GAT: D CATO H	I Q TTC F GGA G ACG	P GCG2 A CGG6 R GAC2 D	E R AGCAC S I GACAA D I ACCCA T I GGCTC	
TCCAGGAACA	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG	T R GCTGCA L C GACCTO T W CAGCTI S F CATCAI	T AGCTG L GGAGG V R TCAAT 7 N	P GAC D CAG Q GTG V GAC	V CGGC R AGCC S ICCC S IGTG	S C AGAA Q K CCCAC P T TGCA L Q	F ACCC P CTGC C GCCC P AGAC	T CCAC H CCAC H SGAG E CCAA	I CAGi Q AACi M AAGi K GTG'	Q AGCCZ T AACCZ T AATC N	M C GGCGC R R CGGCGC T A GAGAA G D	V GGTG V CTTC F CGCC A AAAG	G CTG L CTC L CTC L CTC	A CTG4 L CGG4 R ACG <sup>2</sup> T	T CTG L GAT D TTC. F	G GCTT A GAGC E ATGC M	H CCCC S CCCC L SCCC	N Q GAT: D CATO H	I Q TTC F GGA G ACG	P GCG2 A CGG6 R GAC2 D	E R AGCAC S I GACAA D I ACCCA T I GGCTC	
$\begin{array}{c c} \mathbf{A}\mathbf{T}\mathbf{T}\mathbf{G}\mathbf{T}\mathbf{G}\mathbf{T}\mathbf{C}\mathbf{C}\mathbf{A}\\ \mathbf{V} & \mathbf{C} & \mathbf{V} & \mathbf{Q}\\ \mathbf{T}\mathbf{G}\mathbf{C}\mathbf{G}\mathbf{C}\mathbf{C}\mathbf{T}\mathbf{A}\mathbf{A}\mathbf{A}\\ \mathbf{L} & \mathbf{R} & \mathbf{L} & \mathbf{N}\\ \mathbf{T}\mathbf{C}\mathbf{C}\mathbf{T}\mathbf{G}\mathbf{G}\mathbf{A}\mathbf{C}\mathbf{C}\mathbf{G}\mathbf{T}\\ \mathbf{V} & \mathbf{L} & \mathbf{D} & \mathbf{V}\\ \mathbf{T}\mathbf{G}\mathbf{A}\mathbf{G}\mathbf{C}\mathbf{C}\mathbf{C}\mathbf{C}\mathbf{A}\mathbf{T}\\ \mathbf{L} & \mathbf{S} & \mathbf{P} & \mathbf{I}\\ \mathbf{T}\mathbf{C}\mathbf{A}\mathbf{G}\mathbf{G}\mathbf{G}\mathbf{A}\mathbf{C}\mathbf{A}\\ \mathbf{A} & \mathbf{Q} & \mathbf{E} & \mathbf{Q} \end{array}$	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG T R	T B GCTGCA L C GACCTC T W CAGCTT S F CAGCTT I I	C T AGCTG 2 L GGAGG V R TCAAT 7 N TCCTG 1 L	P GAC D CAG Q CAG Q CGTG V V GAC D	V R AGCC S ICCCC S IGTG	S C AGAA Q K CCAC P T TGCA L C GGGGA G E	F ACCC P CTGC C GCCC P AGAC	T CCAC H CCAC H E GAG E CCAA	I CAGJ Q AACJ M AAGJ K GTG: V	Q AGCC S ACCZ T AATC N IGCC	M C CGGCGC R R T A CGGCGC T A CGGCGC G D TGCCC V P	V GGTG V CTTC F CGCC A AAAG K	G CTC L CTC L CTC L CTC L	A CTG L CGG R ACG T CAG Q	T CTG L GAT D TTC. F CTC L	G GCTT A GAGO E ATGO M TCGO S	H CCCC S CCCC A CTGC L SCCZ A	N Q GAT: D CATO H AACI	I Q TTCO F GGA0 G ACGJ T	P GCGJ A CGGG R GACJ D ACAO T	E R AGCAC S I GACAA D I ACCCA T I GGCTC G S	CT T AG K AC H CC
ATTGTGTCCA V C V Q TGCGCCTAAA L R L N TCCTGGACGT V L D V TGAGCCCCAT L S P I TTCAGGAACA V Q E Q CACTCCTAGT	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG T R TGGAGC	T B GCTGCA L C GACCTCC T P CAGCTT S F CATCAT I I TGATAA	T AGCTG 2 L GGAGG V R TCAAT 7 N TCCTG 1 L ATGTG	P GAC D CAG Q CAG CAG V V GAC D	V CGGC R AGCC S ICCC S IGTG G AGCC	S C AGAA Q K CCCAC P T TGCA G E TGCA	F ACCCC P CTGC C GCCCC P AGACC D	T CCAC H CCAC H SGAG E CCAA Q SGTC	I CAG2 Q AAC2 N AAG2 K GTG2 V GCG0	Q AGCCZ T AACCZ T AATC N IGCC GCCZ	M C GGCGG R R T A GGAGAG G D TGCC2 V P ATGAG	V GGTG V CTTC F CGCC A AAAG K GGGC	G CTG L CTC L CTC L CTC L CTC L	A CTG4 L CGG4 R ACG <sup>2</sup> T CAG4 Q GGA4	T CTG L GAT D TTC F CTC L GCC	G GCT: A GAG( E ATG( M TCG( S CAT(	H FCCC S SCTC A CTGC L SCC2 A SAGO	N Q BAT: D CATO H AACI	I Q TTCO F GGAO G ACGJ T GAGO	P GCG2 A CGG4 R GAC2 D ACA4 T CTG4	E R AGCAC S I GACAA D I ACCCA T I GGCTC G S GTTGI	C T A G K A C H C C S T G
ATTGTGTCCA C V Q FGCGCCTAAA C R L N FCCTGGACGT V L D V FGAGCCCCAT C S P I FTCAGGAACA V Q E Q CACTCCTAGT P L L V F I	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG T R TGGAGC G A	T R GCTGCA L C GACCTC T W CAGCTT S F CATCAT I I TGATAA D N	C T AGCTG 2 L EGAGG V R FCAAT 7 N FCCATG 1 L ATGTG 4 V	P GAC D CAG Q CGTG V GGTG D CTG L	V R AGCC S ICCC S IGTG G AGCC E	S C AGAA Q K CCCAC P T TGCA G E TGCA L H	F ACCC P CTGC C GCCC P AGAC D CCTC C V	T ECAC H ECAC H EGAG E CCAA Q SGTC V	I Q AACI AAGI K GTG: V GCGQ A	Q AGCCZ T AATC N IGCC GCCZ A	M C GGCGG R R R T A GGAGAG G D TGCC: V P ATGAC N E	V GGTG V CTTC F CGCC A AAAG K GGGC G	G CTC L CTC L CTC L CTC L CTC L CTC L CTC L CTC L	A CTG4 R ACG <sup>4</sup> T CAG4 Q GGA4 G	T CTG L GAT D TTC. F CTC L GCC A	G GCT: A GAGC E ATGC M TCGC S CATC H	H S S C T G C T G C C Z S S C Z S S S C Z S S S S S S S S	N Q G G G CATC H A A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A C C A C C C C	I CAGQ Q TTTCQ F GGGAQ G GAGQ E	P GCG3 R GGG4 R GAC2 T CTG4 L	E R AGCAC S I GACAA D I ACCCA T I GGCTC G S GTTGT V V	C T AG K AC H C C S S
ATTGTGTCCA V C V Q GCGCCTAAA L R L N FCCTGGACGT V L D V FGAGCCCCAT L S P I FTCAGGAACA V Q E Q CACTCCTAGT P L L V ACCTGCCCCC	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG T R TGGAGC G A ACGTGC	T R GCTGCA L C GACCTC T V CAGCTT S F CATCAT I I TGATAA	C T AGCTG 2 L GGAGG V R TCAAT 7 N TCCTG L L ATGTG V V	P GAC D CAG Q GTG V GAC D CAG	V CGGC R AGCC S ICCC S IGTG G GAGC E GCCC	S C AGAA Q K CCCAC P T TGCA G E TGCA L H TTCAG	F ACCC P CTGC C GCCC P AGAC D CGTC V CAAC	T CCAC H CCAC H SGAG E CCAA Q SGTC V CACC	I CAGJ Q AACJ K AAGJ K GTG Q GCGQ A AAGJ	Q AGCCZ T AAATC C G G G C A AGCCZ A	M C GGCGG R R T A GGAGAG G D TGCC2 V P ATGCC2 N E TCGAG	V GGTG V F CGCC A AAAG K GGGC G	G CTG L CTC L CTC L GAG E CTC	A CTG L CGG R ACG T CAG Q GGA G G	T L GAT D TTC. F CTC L GCC A	G GCT: A GAGG E M GAGG S CATG H P P ACCC	H SCCC A CTGC L SCCZ A SAGC E 2 CAG2	N Q GAT: D CATC H AACJ AACJ	I CAGG Q TTTCC F GGAA G GACG2 T T GGAGG E	P GCG2 R GGCG R GGCC D ACA4 T CTG4 L GGGG	E R AGCAC S I GACAA D I ACCCA T I GGCTC G S GTTGI V V AATGA	
ATTGTGTCCA C V Q FGCGCCTAAA C R L N FCCTGGACGT V L D V FGAGCCCCAT C S P I FTCAGGAACA V Q E Q CACTCCTAGT P L L V F I	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG T R TGGAGC G A ACGTGC	T R GCTGCA L C GACCTC T V CAGCTT S F CATCAT I I TGATAA	C T AGCTG 2 L GGAGG V R TCAAT 7 N TCCTG L L ATGTG V V	P GAC D CAG Q GTG V GAC D CAG	V CGGC R AGCC S ICCC S IGTG G GAGC E GCCC	S C AGAA Q K CCCAC P T TGCA G E TGCA L H TTCAG	F ACCC P CTGC C GCCC P AGAC D CGTC V CAAC	T CCAC H CCAC H SGAG E CCAA Q SGTC V CACC	I CAGJ Q AACJ K AAGJ K GTG Q GCGQ A AAGJ	Q AGCCZ T AAATC C G G G C A AGCCZ A	M C GGCGG R R T A GGAGAG G D TGCC2 V P ATGCC2 N E TCGAG	V GGTG V F CGCC A AAAG K GGGC G	G CTG L CTC L CTC L GAG E CTC	A CTG L CGG R ACG T CAG Q GGA G G	T L GAT D TTC. F CTC L GCC A	G GCT: A GAGG E M GAGG S CATG H P P ACCC	H SCCC A CTGC L SCCZ A SAGC E 2 CAG2	N Q GAT: D CATC H AACJ AACJ	I CAGG Q TTTCC F GGAA G GACG2 T T GGAGG E	P GCG2 R GGCG R GGCC D ACA4 T CTG4 L GGGG	E R AGCAC S I GACAA D I ACCCA T I GGCTC G S GTTGI V V AATGA	
ATTGTGTCCA C V Q CGCGCCTAAA C R L N CCTGGACGT 7 L D V CGAGCCCCAT C S P I TCCAGGAACA 7 Q E Q CACTCCTAGT P L L V ACCTGCCCCC I L P P	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG T R TGGAGC G A	T R GCTGCA L C GACCTC T V CAGCTT S F CATCAT I I TGATAA D N TCACTA H Y	C T AGCTG 2 L EGAGG V R TCAAT 7 N TCCAAT 6 L L ATGTG 1 V ACATG 2 M	P GAC D CAG Q CGTG V GGAC C D GCTG C C GAC C L	V CGGCC R AGCCC S FICCCC S G G G G G G G G G C C A	S CAGAA Q K CCCAC P T TGCA L Q GGGA G E TGCA L H TCAG L S	F ACCCC P CTGC C G GCCCC D C AGACC D C C C C C C C C C C C C C C C C C	T CCAC H CCAC H GGGAG E CCAA Q CCAA Q CCCAA V CACC V CACC T	I CAG2 Q AAAC2 N AAAG2 K GTG? V GCGG A AAAG2 K	Q AGCCZ T AAATC N IGCCZ A GCCZZ A AGCCZ S	M C GGCGC R R R ACCGCC T A GGAGAA G D TGCC2 V P ATGCC N E TCGAA F E	V GGGTG V F CGCCC A AAAAG K G GGGCC G R	G CTG L CTC L CTC L CTC L CTC L CTC L CTC L	A CTG4 R ACG <sup>2</sup> T CAG <sup>4</sup> Q GGA4 G ATC I	T CTG4 L GAT4 D TTC. F CTC4 L GCC4 A	G GCT: A GAGG E AATGG M TCGG S CATG H P ACCC T	H S S S S S S S S S S S S S S S S S S S	N Q Q BAT: D CATO H AAC: A AC: A AC: A AC: A AC: A CACC A A AC: A CACC A A AC: A CACC A A CACA A CACA A C A A C A C	I CAGU Q TTCC F GGAU G ACGJ T CAGGU K	P GCG2 A CCGG4 R GAC2 D ACA4 T CTG4 L GAG2 E	AGCACA AGCACA D I ACCCCA T I GGCTC G S GTTGI V V AATGA I I	C T AG K AC H C C S S C C S S C C S S S S S S S S
ATTGTGTCCA $V \subseteq V Q$ $V \subseteq R L N$ $V \subseteq R L N$ $V \subseteq Q$ $V \subseteq Q$	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG T R TGGAGC G A AGCTGC G A GCTGTG	T F GCTGCZ L C GACCTC T F CAGCTT S F CAGCTT I I TGATAZ H Y TGAGCT	C T AGCTG 2 L GGAGG V R TCAAT F N TCCTG L L ATGTG V V ACATG C M TGGGGC	P GAC D CAG Q CGTG U CGTG L CAG Q CCTG Q CCTG Q	V CGGCC R AGCCC S ICCCC S ICCCC A GCCCCA	S CAGAA Q K CCCAC P T TGCA G E TGCA G E TGCA L H TCAG L S L S	F ACCC P CTGC G G CCCC D AGAC D CCTC V CAAC N GGGGC	T CCAC H GCAC E GCAA Q CCAA Q CCAA Q CCAA V CCAC T CCAC T	I CAG2 Q AAAC2 M AAAG2 K GTG2 V GCGG A AAG2 K AAG2 K AACCC	Q AGCCZ S AACCZZ T AAATCC N IGCCZ A AGCT S CAGZ	M CGGCGG R R R CGGCGG T A GGAGAG G D TGCCC V P AATGAO N E TCGAG F E	V GGTG V CTTCC F CCGCC A AAAAG K GGGGC G R SAGC R	G CTG L CTCC L CTCC L CTCC L CTCC L CTCC L CTCC L CTCC L	A CTG4 L CGGG R ACCG <sup>*</sup> T CAG4 Q GGA4 G GGA4 G I ATC <sup>*</sup>	T CTG4 L GAT4 D TTC. F CTC7 L GCC4 A TGT	G GCT: A GAGC E ATGC M TCGC S CATC H P ACCC T T GTG2	H FCCCCS S CTGC L S CTGC E S S CCCZ A S S CCCZ A S S CCCZ A S S CCCZ A S S CCCCC A S S C CCCCC S S S C C C C	N Q Q J D CATO H AACC A AACC A AACC A CATO A ACC A CATO A ACC A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A A A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CATO A CA A CA	I CAGU Q TTCC F GGAU G GAGU E CAGGU K GGGG	P GCGG R GGCG D ACAC T CTGC L GAGG E	AGCACA S I GACAA T I GGCTC G S GTTGT V V AATGA N I CTGGA	
ATTGTGTCCA V C V Q GCGCCTAAA L R L N FCCTGGACGT V L D V FGAGCCCCAT L S P I FTCAGGAACA V Q E Q CACTCCTAGT P L L V ACCTGCCCCC	P Q TGCCGA A E GGATCT D L CGTGCT V L GACCCG T R TGGAGC G A ACGTGC G A ACGTGC G A	T R GCTGCA L C GACCTC T W CAGCTT S F CATCAT I I TGATAA H Y TGAGCT E I	C T AGCTG C L GGAGG V R TCAAT F CCAAT F CCTG L L ATGTG V V ACATG C G C G	P GAC Q GGTG V GGAC D GGAC L CAG Q Q CAACO N	V R AGCCC S ICCCC S IGTG G S AGCCC A P	S C AGAAA Q K CCCAC P T TTGCA L Q GGGA G E TTGCA L H TTCAG L S TTGAA M K	F ACCCC P CTGC G G G CCCCC D CCACC V CCAAC V CCAAC V G G G G G	T CCAC H GGAG E CCAA Q GGTC V CACC T GGAC D	I Q AACJ N AAGJ K GTG' V GCGC A AAGJ K AAGJ K AACCC T	Q AGCCZ T AAATC N IGCC G G G G G C AGC S C AGC Q	M CGGCCG R R R CGGCCG T A GGAGAG G D TGCCC V P AATGAC N E TTCGAG F E TTCGAG I E	V GGGGG V CTTCC F CCGCC A AAAAG K GGGGC G R AAATCC I	G CTG L CTCC L CTCC L GAG E CTC L CTC L CTC C L CTC C T C T	A CTG L CGG4 R ACG T T CAG4 G G G ATC I M	T CTG4 L GAT( D TTC. F CTCC L GCCC A TGT L TTG4 L	G GCT: A GAGC E ATGC M TCGC S CATC H P ACC T GTG2 V	H FCCCS S CTGC L S S CTGC E S S S S S S S S S S S S S S S S S S	N Q Q BAT: D CATC H AAC: A AC: A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A CATC A C C CATC A C C C C	I CAG4 Q F GGA4 G GAG4 E GAG4 K GGG2 G	P GCG3 R GGG4 T CTG4 L GAG2 E N	E R AGCACA S I GACAAA D I ACCCAA T I GGCTC G S STTGI V V AAATGA N I CTGGAA L E	






Fig. 2. The nucleotide and deduced amino acid sequences of pig *CD41* cDNA. The predicted signal peptide is remarked in light green, the transmembrane domain in dark green, and the cytoplasmic region, containing the GFFKR sequence, in purple. The putative polyadenylation sequence is remarked in a black box. Potential N-glycosylation sites are indicated in red. Cysteine residues are marked as C in yellow. Putative cleavage sites are shown as  $\blacktriangle$ . Ca++ binding domains are remarked in pink. Primers used for cloning are marked with arrowheads.




Fig. 3. Secondary structure of the porcine CD41 molecule. Sequences in  $\beta$  antiparallel sheets are shown in green.




Fig. 4. Three-dimensional structure of the porcine CD41 molecule. The seven FG-GAP tandem repeats are shown as W, each one composed by four  $\beta$  antiparallel chains.

#### 3.2 Comparative analysis

The deduced protein sequence of the porcine CD41 was compared to their orthologous proteins from six different species: humans, cattle, horses, dogs, rats, rabbits, mice, zebrafish and xenopus (Figure5 and Table2).

DTC	MARALCLLHALWLLEWVOLLLGPGAAPPTWALNLDPVHLTIYTGPNGSHFGFSLDFYKKS	60
PIG HUMAN	MARALCHLAALWILLEWVQIILLGPGAAPP1WALINLDPVNIIIIIIGPNGSRFGFSLDFIKKS MARALCPLQALWILEWVIILLGPCAAPPAWAINLDPVQIIFYAGPNGSQFGFSLDFHKDS	
HORSE	MARALRPLHALWLLEWNQLLLGPGTAPQAWALNLDPVRLTFYTGPNGSHFGFSLDFYKDS	
RABBIT	MARALGPLPAFWFLEWALLLLGPGAGPPAWALNLDPVQLTIYTGLNGSHFGFSLDFYKDS	60
DOG	MARAVCPLNALWLLEWVQLFLGPGAIPLGWALNLDPVQLTFYTGPNGSHFGFSLDFYKDN	60
COW	PTWALNLDSVQFTVYTGP <mark>N</mark> GSHFGFSLDFYKNS	
RAT	MARASCAWNTLWLLQWTPLFLGPSAAPPAWALNLDPVKFSVYTGP <mark>N</mark> GSHFGFSVDFHKDS	60
MOUSE	MARASCAWHSLWLLQWTPLFLGPSAVPPVWALNLDSEKFSVYAGP <mark>N</mark> GSHFGFSVDFHKDK	60
ZEBRA FISH	MDKKLEFSLLFLSILIFTNHIRGFNLDLNQYTVFSGPEDSYFGFSVDFYQSS	
XENOPUS	MVPWLLLLLPAFIQNLNLDK-KPQTLSGPPGSHFGFSMDFYNTA	43
PIG	HGSVSIVVGAPRTLGRNLEETGGVFLCPWKAKSVQCVALSFNLD-DETRNVGAQTFQT	117
HUMAN	HGSVSIVVGAPRILG-PROLEEIGGVFLCPWRARSVQCVALSFNLD-DEIRNVGAQIFQI HGRVAIVVGAPRTLG-PSQEETGGVFLCPWRAEGGQCPSLLFDLR-DETRNVGAQIFQI	
HORSE	RGSVSIVVGAPRTLGRSQEEMGGAFLCPWKAEGGQCTSLSFDLN-DETRNVGSQIFQT	
RABBIT	HGSVAIVVGAPRTLGLGQKETGGVFLCPWKAEGSPCSLLSFNLS-DEYRKTSSQLFQT	
PERRO	HGRVAFVVGAPRTLGRSQEETGGVFLCPWRAEGGQCTSLPFDLN-DETRHIGSHTFQT	
COW	NGSVYVVVGAPRTLGHSEEETGGVFLCPWKAEGGOCISLPFDLY-DETRSIGTOTFOT	
RAT	HGSVSIVVGAPRALNANQEETGGVFLCPWKANNGTCTSLLFDLR-DETRKLSFQTFQT	
MOUSE	HGSVSIVVGAPRALNASQEETGAVFL <mark>C</mark> PWKANGGK <mark>C</mark> NPLLFDLR-DETRNLGFQIFQT	117
ZEBRA FISH	SKSVSVVVGAPRANTNQSGVSHGGSVFM <mark>C</mark> PWATRGQS <mark>C</mark> QTLNFDQKGDENITFGNMLLMA	112
XENOPUS	DQGMSIVVGAPRMQTSQRNVTMGGGVFL <mark>C</mark> PWKPKGSS <mark>C</mark> VNIKFDSTGDRSIPFAGYTMKI	103
DIC		176
PIG HUMAN	~ ~ ~	176 176
HOMAN	~ ~ ~	176
RABBIT		176
DOG		176
COW		150
RAT		176
MOUSE		176
ZEBRA FISH	HKSNQWLGASVRTYNNYILACAPLFHWNVLVDQEE-AMNTPVGNCQLLNMKTGELANYAP	171
XENOPUS	FKSNQWFGATVRTWNTAIVA <mark>C</mark> APFQQWNVMKLGSE-SGTTPTGT <mark>C</mark> YITNN-LEDIYEFAP	161
DIC		235
PIG HUMAN		235 236
HORSE		235
RABBIT	CRGNTMSHVYEKMYLRD-LRSCEAGFSSVITQEGELVLGAPGGYYYLGFLVRAPIANIIS	
DOG	CRANTMSSVYVKNRFNQDKRYCEAGFSAAVTQAGVLVLGAPGGYFFLGLLVRTPIDNIIS	
COW	CRDNKMSQFYERNHFRDDRRYCEAGFSSVVTXAGELVLGAPGGYYFVSLLARAPIADIIS	
RAT	CRSNTMSSVYSQGFSGD-KRYCEAGFSLAVTQAGELVLGAPGGYFFLGLLVRVPIENIIS	
MOUSE	CRANTMSSVYAESFRGD-KRYCEAGFSLAVTQAGELVLGAPGGYFFLGLLARVPIENIIS	235
ZEBRA FISH	CREEYVYAIYTRGYPDRRYCEAGFTTDITKNGRVVLGAPGGYYFQGQIITASLVNIMS	229
XENOPUS	CRESKMERHYEADRRFCELGFSTDINKDGTLLAGAPWG-YFQGLYVTAGLPNILA	215
DTC	SYRPGTLLWHVPTQKLTFDSDLPEYYESYLGYSVAV <mark>GEFDRNP<mark>N</mark>TTEYI</mark> LGGPTWSMTLG	205
PIG HUMAN	SIRPGILLWHVPIQKLIFDSDLPEIIESILGISVAVGEFDRNPNIIEIILGGPIWSMILG SYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTTEYVVGAPTWSWTLG	
HORSE	SYRPGILLWRVSSQSLSFDSSNPEIFDGIWGISVAVGEFDGDLMIIEIVVGAPIWSWILG SYRPGILLWSVPTQRFTFDSMKPEYFDGYRGYSVAVGEFDEDLSTTEYVFGAPTWSWILG	
RABBIT	SYSPGVLLWTVPNQNFTFDYSNRKYFDGYRGYSVAVGEFDGDLSTTEYVGAPTWSWTIG	
DOG	SYRPGTLLWHVSSQSFTYDYSKPEYYDGYRGYSVAVGEFDGNL <mark>M</mark> TTEYVLGAPTWSCTLG	
COW	SYRPSTLLWHVPTQ-FTYDQSHLQYYDGYRGYSVAVGNFDGNP <mark>N</mark> TTEYVFGAPTWSWTLG	
RAT	TYRPGTLLWHVSNQRFSYDSSNPVYFHGYRGYSVAVGEFDGDLSTTEYIFGAPTWSWTLG	
MOUSE	TYRPGTLLWHVSNQRFTYDNSNPVFFDGYRGYSVSVGEFDGDPSTTEYVSGAPTWSWTLG	
ZEBRA FISH	SGSSFTPKHSMNGETKTPQRRDYYDLYLGYSVAAGKFNND- <mark>N</mark> IPDYVVGVPNDLHTAG	
XENOPUS	RPASSSLLQSYPGQQISPYIGSSFDSYKGFSVAYGEFTGD- <mark>N</mark> TPEIVVGSP-KYQDRG	271

HUMAN HORSE RABBIT DOG COW RAT MOUSE ZEBRA FISH XENOPUS PIG HUMAN HORSE RABBIT DOG COW RAT MOUSE ZEBRA FISH XENOPUS PIG HUMAN HORSE RABBIT DOG COW RAT MOUSE ZEBRA FISH XENOPUS

PIG

PIG HUMAN HORSE RABBIT DOG COW RAT MOUSE ZEBRA FISH XENOPUS

PIG HUMAN HORSE RABBIT DOG COW RAT MOUSE ZEBRA FISH XENOPUS

PIG HUMAN HORSE RABBIT DOG COW RAT MOUSE ZEBRA FISH

XENOPUS

AVEIFT---SKHQRLHLLQGEQVASYFGHSVAVT<mark>DVNGDGRHDLLV</mark>GAPLYMESRADHKL 352  ${\tt AVEILD---SYYQRLHRLRAEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKL}$ 353 352 AVEILD---SNFQMLHRLHGEQMASYFGHSVAVTDVNGDRRHDLLVGAPLYMERRADRKL  $\label{eq:average} AVEILD---SYFYRLHRLQGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLFMASQADHKL$ 352 AVEILN---EYHQTLHRLHGEQMASYFGHSIAVTDVNGDGRHDLLVGAPLFMESRADRKL 353 326  ${\tt AVEILD---SYHQMLHRLHGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKL}$ AVEILD---SYYQTLHRLHGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRVDRKL 352 AVEILD---SYYQPLHRLHGEQMASYFGHSVAVTDVNGDGRHDLLVGAPLYMESRADRKL 352 SVKIINGATVPLQIMKAISGTQIASYFGHSVAVTDINRDGWDDILIGAPLFMEQLSTQKF 346 LVDIYT-VSNPWKTFISFLGKQVASYFGHSVAVTDVNNDGRDDVLVGAPLFMERRTRGKL 330 AEVGRVYLFLQSRGHHSLGTPSLLLTGTQLYGRFGSAIAPLG<mark>DLNRDGYNDVAV</mark>AAPYGG 412  ${\tt AEVGRVYLFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDRDGYNDIAVAAPYGG}$ 413 AEVGRVYLFLQPRSPQPLGPASLLLTGTRIYGRFGSAIAPLGDLNRDGYNDVAVAAPYGG 412  ${\tt AEVGRVYLFLQLQGPHLLGAPSLLLTGTQLYGRFGSAIAPLGDLNRDGYNDVAVAAPYGG}$ 412  ${\tt AEVGRVYLFLQPRGHQALGAPSLLLTGTQLYGRFGSAIASLGDLDRDGYNDVAVAAPYGG}$ 413  ${\tt AEVGRVYLFLQTRGARMLGAPNLLLTGTQLYGRFGSAIAPLGDLNRDGYNDVAVAAPCGG}$ 386  ${\tt AEVGRVYLFLQPKGLQALSSPTLVLTGTQVYGRFGSAIAPLGDLNRDGYNDVAVAAPYGG}$ 412  ${\tt AEVGRVYLFLQPKGPQALSTPTLLLTGTQLYGRFGSAIAPLGDLNRDGYNDIAVAAPYGG}$ 412 REVGQVYVYLQRNDFSFASRPNQILAGTYAYGRFGSAIAPLGDLDHDGFNDVAVGAP--G404 QEFGQVYVYLQRENRKFSFN-HPVLTGSQVYGRFGSSIAPLGDIDQDGFNDVAVGAPFGG 389 PTGQGQVSVFLGQSEGLNSQPSQVLHSPFA---AGSAFGFSLRGAT<mark>DIDDNGYPDLLV</mark>GA 469 PSGRGOVLVFLGOSEGLRSRPSOVLDSPFP---TGSAFGFSLRGAVDIDDNGYPDLIVGA 470 PDGRGQVLVFLGQSEGLSSHPSQVLDSPFS---TGSAFGFSLRGATDIDDNGYPDLLVGA 469 PSGRGQVLVYLGQSEGLNPHPSQVLDSPFP---AGSAFGFCLRGATDIDDNGYPDLLVGA 469 PSSLGQVLVYLGQSEGLSSRPSQILDSPFP---AGSGFGFSLRGATDIDDNGYPDLLVGA470 PNGQGQVLVYLGQSEGLNPSPSQVLDSPFP---TGSGFGFSLRGATDIDDNGYPDLLVGA 443  $\texttt{PSGQGQVLIFLGQSEGLSPRPSQVLDSPFP}{--}{-}\texttt{TGSGFGFSLRGSVDIDDNGYPDLIVGA}$ 469 PSGQGQVLIFLGQSEGLSPRPSQVLDSPFP---TGSGFGFSLRGAVDIDDNGYPDLIVGA 469 SVDGGKVFIYLGKSGGLSTQYVQVIESPFRSLIDPPMFGFSIRGGTDIDDNGYPDLIIGA 464 ESGGGCVFIYRGSPAGLSPQPSQILESPLP---PPAQFGFALRGGMDIDNNGYPDLLVGA 446 YGADKVVVYRAQPVVTATVQLMVQ-ESLNPAVKN<mark>C</mark>VQPQTKTPVS<mark>C</mark>FTIQM<mark>C</mark>VGATGHNI 528 YGANQVAVYRAQPVVKASVQLLVQ-DSLNPAVKS<mark>C</mark>VLPQTKTPVS<mark>C</mark>FNIQM<mark>C</mark>VGATGHNI 529 YGANKVAVYRAQPVVMVSVQLLVN-DSLNPAVKNCVLPQKKTSVS<mark>C</mark>FDIQM<mark>C</mark>VGVTGHNI 528 YGADKVVVYRAQPVVMADVQLLVQ-DSLNPAVKN<mark>C</mark>VLHQTNTPVS<mark>C</mark>FNIQM<mark>C</mark>VGVTGHNI 528 YGASKVAVYRAQPVVVANVQLLVQ-DSLNPAVKNCILPQTKTPVSCFNIQMCVGATGHNI 529 YGASKVVVYRAQPVVMVTVQLMVQ-DSLNPAVKTCVLSQTKTPVSCFNIQMCVGATGHNI YGASKVAVYRAQPVVMATVQLMVQ-DSLNPTLKNCVLEQTKTPVSCFNVQMCVGATGHNI 502 528 YWASKVAVYRAQPGVMATVQLMVQ-DSLNPTLKNCVLDQTKTPVSCFNIQMCVGATGHNI 528 WGASKVVTYRAQAVVRTQARLSFFPDLLNPEDKFCQLQQSGTYITCFTIMACIRVSGHRI 524 FHADKVFIFRTQPVVVLQASLFFNPEALNPDEKL<mark>C</mark>NFPQSGPAVS<mark>C</mark>FTIRV<mark>C</mark>AQASGRSL 506 PEKLRLNAELQLDRQKPHQSRRVLLLASQQASTVLDVDLTWRQSPTCHNTTAFLRDEADF 588 PQKLSLNAELQLDRQKPRQGRRVLLLGSQQAGTTLNLDLGGKHSPICHTTMAFLRDEADF 589 PEKLRLNAELQLDRQKPRQGRRVLLLSSQQAGTTLHLDLGGRTSPNCRTIEAFLRDEADF 588 PQGLYLQAELQLDRQKPRQGRRVLLLGSQQASTTLSMDLGGRQSRL<mark>C</mark>H<mark>N</mark>TTAFLRDEADF 588 PQQLSLNAELQLDRQKPRQGRRVLLLNSQLASSTLHLDLGGRHSPI<mark>C</mark>HTTTAFLRDEADF 589 PEKLHLNAELQLDRQKPRQGRRVLLLDSQQAGTILNLDLRGRHNPN<mark>C</mark>STATAFLRDEADF 562 PQKLHLKAELQLDLQKPRQARRVLLLASRQASLTLSLDLGGRNKPI<mark>C</mark>HTIKAFLRDEADF 588 PQKLHLKAELQLDLQKPRQGRRVLLLASQQASLTLSLDLGGRDKPI<mark>C</mark>HTTGAFLRDEADF 588 PQQIVFNTELQLDRMKQSMARRTLLLDSNQPYTNFQISVDRNSRDV<mark>C</mark>R<mark>M</mark>FTAYLLP--EF 582 PKKISLSAELQLDRLKSRFARRTFFLDSSQPSKTIDMELQSNSAQLCQNLTPYLRGESEF 566 RDKLSPIVLSF<mark>N</mark>VSLQPEKNGDALTFMLHGDTHVQEQTRIILD<mark>C</mark>GEDQV<mark>C</mark>VPKLQLSA<mark>N</mark>T 648 RDKLSPIVLSLNVSLPPTEAGMAPAVVLHGDTHVQEQTRIVLDSGEDDV<mark>C</mark>VPQLQLTASV 649 RDKLSPIVLSL<mark>N</mark>VSLQPEKDGIAPALVLHGDTHVQEQTRIILD<mark>C</mark>GEDDL<mark>C</mark>VPQLHLTA<mark>N</mark>V 648 RDKLSPIVLSFNVSLQPKEAGVAPAVVLHGNTHVQEQTRIILECGEDDVCVPQLHLTASL 648 RDKLSPIVLSL<mark>N</mark>VSLQPRKDGVAPAIVLHGDTHVQEQTRIILD<mark>C</mark>GEDDL<mark>C</mark>VPQLQLTAIV 649 RDKLSPIVLSFSVSLPPEKDGGAPALVLHGNTHVQEQ-599 RDKLSPIVLSL<mark>N</mark>VSLPPEETGVAPAVVLHGVTHVQEQTRIILD<mark>C</mark>GEDNL<mark>C</mark>VPQLQLTATA 648 RDKLSPIVLSLNVSLPPEETGGAPAVVLHGETHVQEQTRIILDCGEDDLCVPQLRLTATA 648 KDKLSPIFISVNYSLADSQ----NAVLHGQSVAVGQTRIILNCGPDNVCIPDLQLKAVT 637 KDKLSPIAMSV<mark>N</mark>FSLVRAQSMDTVQPTLHGTTFLQEQTNILLD<mark>C</mark>GDDNV<mark>C</mark>IPNLHLTA<mark>N</mark>W 626

#### Molecular Cloning - Selected Applications in Medicine and Biology

PIG TGSPLLVGADNVLELHVVAANEGEGAHEAELVVHLPPGAHYMOALSNTKSFERLICTOKK 708 HUMAN TGSPLLVGADNVLELQMDAANEGEGAYEAELAVHLPQGAHYMRALSNVEGFERLI<mark>C</mark>NQKK 709 HORSE TGSPLLIGADNVLKLOMDATNEGEGAYEAELAVOLPPGAHYMOALSNIEGFERLICOOKK 708 RABBIT KGSPLLIGADNVLELQMVAANDGEGAYEAELVVHLPLGAHYMRAVSTMEGLERLI<mark>C</mark>NQRK 708 DOG MGSPLLIGADNVLELOMDAANEGEGAYEAELAVHLPPGAHYMRAISNIEGFERLICNOKK 709 COW -----GFERLI<mark>C</mark>NOKK 610 RAT GDSPLLIGADNVLELKVNASNDGEGAYEAELAVHLPPGAHYIRAFSNVKGFERLVCTQKK 708 MOUSE GDSPLLIGADNVLELKIEAANDGEGAYEAELAVHLPPGAHYMRALSNIEGFERLVCTOKK 708 ZEBRA FISH STEPILIGDENPALLIIEAENQGEGAYETELYISPPANTHYQGVLSNHEDFSALVCGQKK 697 XENOPUS SADPLLIGIDNLVHVQFNAANLGEGAYEAELYVWLPNGAHYMQVLG--EAEEKIL<mark>C</mark>SPKK 684 NETKVVL<mark>C</mark>ELGNPMKGDTQIEITMLVSVGNLEEAGEHVSFRLQIRSKNSQNPNSETVVL PIG 768 HUMAN E ETRVVL<mark>C</mark>ELGNPMKKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLL 769 HORSE E ETKVVL<mark>C</mark>ELGNPMKRNAQIEITMLVSVENLEEAGETVSLQLQIRSKNSKNPNSETLRL 768 RABBIT QTKAVL<mark>C</mark>ELGNPMK-QARIGITMLVSVGNLEDAGESVSFQLQIRSKNSQNPNSEAVLL 767 Ε DOG Е ETKIVLCELGNPMKRNARIGITMLVSVENLEEAGEHVSFWLQIRSKNSONPNSEAVLL 769 COW Е ETKVVLCELGNPMKSNAQIEVMMWVSVEKLEEAGEQVSFLLQIRSKNSQNPNSEMVEL 670 RAT Е ESRLAL<mark>C</mark>ELGNPMKKDTRIGITMLVSVEILEEAGDSVSFQLQIRSKNSQNPNSEAVLL 768 MOUSE Е ESRVALCELGNPMKKDTRIGITMLVSVENLEEAGESVSFOLOVRSKNSONPNSKVVML 768 ZEBRA FISH Е GSVIVV<mark>C</mark>DLGNPLEAGQQLKAGLYFSMGDLEQVENHITFQMQIRSKNSQNSDSNLVQL 757 XENOPUS ESEIVV<mark>C</mark>ELGNPMKNGAEIHADLQLSFSNLEDSGSTVTFQMQIKSRNTVNSASSLFLV 744 PIG DVQVRAEAHLELRGNSFPASLLMAA-EGDWE---NSSDNLGPKVEHTYELHNNGPSTVSG 824 HUMAN DVPVRAEAOVELRGNSFPASLVVAAEEGEREO--SLDSWGPKVEHTYELHNNGPGTVNG 827 HORSE HVPVRAEARVELRGNSLPASLVVAAEEDDRK--SSDSWGPKVEHTYELHNNGPGAVRG 825 RABBIT AVPVRAAAQVELRGNSFPASLVLAEEGDQEQ----NSLDLKVEHTYELHNNGPGTVRG 821 DOG DVPVRAEAHVKLRGNSFPASLVVVAEEDNRE--SSESWGPKVEHTYELHNNGPGTVSG 826 COW DVPVRAVAHVELRGNSFPASLVVAAEEGNGQ--NSSDSWGPKVEHTYELHNNGPGAVSG 727 RAT PVAVRAEAAVELRGNSFPASLVVAAEEVDKEQ--DGLDSWVSRVEHTYELHNNGPGTVNG 826 MOUSE PVAIQAEATVELRGNSFPASLVVAAEEGDREQ--EDLDSWVSRLEHTYELHNIGPGTVNG 826 OVNVTAVASLEMRGVSSPVDCVLPISKWESKDYPEDLDEVGPLIEHVYELRNRGPSPVN-ZEBRA FISH 816 XENOPUS TMAVKVTASLELRGSSHPAEVILPLPNWEPREEWRKAQDYGEEVTHVYELHNSGPGSVH-803 LHLRLHLPTGQSQTSDLLYIVDIQTQGGLQ<mark>C</mark>SPQPSPNPRQLDWG--LHSPTPSPVYPAH 882 PIG HUMAN LHLSIHLPG-QSQPSDLLYILDIQPQGGLQCFPQPPVNPLKVDWG--LPIPSPSPIHPAH 884 LRLSLHLPS-QSQPSDLLYILDIQPQGGLQCSPQPSPNPLKLDWG--LPTPSPSPVYHPR HORSE 882 LHLTIHLPG-QSQPSDLLYILGIEPQGGLQCSPQPSPNPLKINWR--LPTPSPSPMHPGY RABBTT 878 LHLHLCFPG-ESQPSDLLYILDIQPEGGLQCSPQPSINPFKLDWR--QPTPSPSPTSPGY DOG 883 LRLNLYLPS-QSQPSDLLYILDIHPQGGLQCASQPSPNPLQLEWR--LPTPSPS---PAH COW 781 RAT LSLIIHLPG-QSQPSDLLYILDVQPKGGLLCSTQPPPKLLKVDRS--LTTPSPSSIRRIH 883 LRLLIHIPG-QSQPSDLLYILDVQPQGGLLCSTQPSP---KVDWK--LSTPSPSSIRPVH 880 MOUSE VKLTLEFPV-SQNESYLLYVFANASEELISCQTDYAN----IDPRRLVKQESTNITVAEV 871 ZEBRA FISH XENOPUS VQLLLQSPE-MYHGDYFLYPLRLEVDDGMT<mark>C</mark>DNQSALNPLKLDILTSTEEPANYSSRSGD 862 HKENEROAUT.-----PCOKOPLSLODDILLSCD\_SAPCTW/HCDLDFMARG PTG 927 HUMAN HKRDRRQIFL-----PEPEQPSRLQDPVLVS<mark>C</mark>D-SAP<mark>C</mark>TVVQ<mark>C</mark>DLQEMARG 929 HORERREAFL-----PGPMQPSRLQDPVLVNCD-SAPCTVVQCELEEMARG 927 HORSE -----pqpssaagprdpvlvs<mark>c</mark>d-sap<mark>c</mark>tvvq<mark>c</mark>elqemarg 924 RABBIT RRERRHADLLE-HKRERRQASL-----PGSSQPSGLQDPVLLSCK-SGPHTVVQCELQEMARG 928 DOG COW HKRDRROAVL---------PEEKQPSRLQDPILVS<mark>C</mark>D-SAP<mark>C</mark>TVVQ<mark>C</mark>ELQEMARG 826 HDRDRREASP------QGSKQTEQQDPVLVS<mark>C</mark>NGSAP<mark>C</mark>TVVE<mark>C</mark>ELQEMVRG RAT 928 924 HQRERRQAFL-----QGPK-PGQQDPVLVS<mark>C</mark>DGSAS<mark>C</mark>TVVE<mark>C</mark>ELREMVRG MOUSE HHFNKRDLS-----QKTENEQQWQHTVHVNCSSSEQCVVFDCVAAGLQRD 916 ZEBRA FISH HRLERRDLRRWGADEGMOEDGVNITKKDEKPPRNHTVLLNCSSFP-CWEVOCSVONLERG XENOPUS 921 QRAMVTAQAFLWLPSLRQRPLDQFVLRSHAWF<mark>N</mark>VSSLPYAVPALSLPSGEAQVQTQVLRV PTG 987 QRAMVTVLAFLWLPSLYQRPLDQFVLQSHAWF<mark>N</mark>VSSLPYAVPPLSLPRGEAQVWTQLLRA QRAMVTVRAFVWLPSLRQKLLDQFVLQSRAWF<mark>N</mark>VSSLPYAVPTLSLPSGEALVQTQLLRV HUMAN 989 HORSE 987 QRAMVTVLALLGLSSLRERPLDQFVLQSQAWFNVSSLPYAVPALSLPSGEALVQTQLLRV QRAMVKVLAFLQLPSLQQRPLDQFVLESQAWFNVSSLPYAVPSLSLPSGETLVQTHLLRA RABBIT 984 DOG 988 QRVMVTVLALLSRSILQERPLDQFVLQSHAWFNVSSHFIAVPSLSHPSGEILVQIHLLKA 988 QRAMVTVQATLGLSILRQRPLDQFVLQSHAWFNVSSFPYSVPALSLPSGEALVQTULLRA 988 QRAMVTVQATLGLSILRQRPQEQFVLQSHAWFNVSSLPYSVPVVSLPSGKALVQTHLLRA 988 COW RAT  $\label{eq:constraint} QRAMVTVQAMLGLSSLRQRPQEQFVLQSHAWF {\bf N} VSSLPYSVPVVSLPSGQARVQTQLLRA$ MOUSE 984 ZEBRA FISH ERAIVRVMSRLWVOTFLKRPYVNYVLHSTAHYEVMNVPSKIOPDVLPTGKAETHTKIIWR 976 GRATVKLHSILWVPSFLKRQQQQFVLLSQGSFWVTSVPYKIQPAVLLYGNATANTTVLWV 981 XENOPUS

PIG	RVLEDR <mark>EV</mark> PLWW <mark>ML</mark> VGVLGGLLLLTLLVLAMWKCGFFKRNRPPLEESDEEEE 1039
HUMAN	LEERAIPIWWVLVGVLGGLLLLTILVLAMWKVGFFKRNRPPLEEDDEEGE 1039
HORSE	LEDRAIPIWWVLVGVLGGLLLLTLLVVAMWKVGFFKRNRPPLEEDEEDE 1036
RABBIT	LEEKAVPIWWVLVGALGGLLLLILLVLAMWKVGFFKRNRLPLEEEDEDEE 1034
DOG	LEERDIPIWWVLVGVLGGLLLLMLLVLAMWKGGFFKRNRPPLEEEEEE 1036
COW	SEEREIPMWWVLVGVLGGLLLLTFLILAMWKVGFFKRNRPPLEEDDEEE0935
RAT	LEERDIPVWWVLVGVLGGLLLLTLLVLAMWKAGFFKRNRPPLEEEEEEE 1037
MOUSE	LEERAIPVWWVLVGVLGGLLLLTLLVLAMWKAGFFKRNRPPLEEDEEEE 1033
ZEBRA FISH	SPDGQEEVPLWWIVVSIVAGLLLLAALSTIFWKMGFFKRNRPPSDNDDDDDDDVTQQLN 1036
XENOPUS	SPDGQKEIPLWWIIVGALGGLLLLALFVFVMWKLGFFRRTRPPSDDQEDLTSD 1034

Fig. 5. Comparison of the porcine CD41 amino acid sequence to other homologous molecules. The sequences were derived from GenBank entries with accession numbers shown in materials and methods. Signal peptide is in green. Heavy and light chains are shown by orange and black lines, respectively. Ca<sup>++</sup> binding domains are remarked in pink boxes. Potential N-glycosylation sites (N) and cysteine residues (C) are respectively marked in red and yellow in the respective sequences. Amino acids residues conserved in all the sequences are shown in light grey.

As shown in Table2, the longest porcine CD41 protein shares a 78% amino acid residue identity with those of humans, cattle and horses, 77% with dogs, 75% with rabbits, 73% with rats, 71% with mice, 42% with *Xenopus laevis* and 40% with zebrafish. Table2 also shows the percentages of amino acid residue identities of the different regions of the CD41 molecule. In general, both transmembrane and cytoplasmic domains are more preserved compared to the extracellular one. The phylogenetic tree of CD41 proteins shows that the counterpart closet to porcine CD41 was that of cows (Figure6).

ESPECIES	PROTEIN	EX TR A C EL LUL A R	T AR N SM EM B RA N E	CYTOPL AS MIC
HUMAN	78	77	80	85
COW	78	77	80	89
HORSE	78	77	80	78
DOG	77	77	80	83
RAT	71	71	84	84
MOUSE	73	72	84	84
RABBIT	75	74	80	80
ZEBRA FISH	40	41	53	55
XENOPUS	42	42	69	4 0

Table 2. Percentages of amino acids identities between the porcine (Po) and its constitutive blocks with those from humans (Hu), cow (Ca), horse (Ho), dog (Do), rat (Ra), mice (Mi), rabbit (Rb), zebrafish (Zf) and *Xenopus laevis* (Xe).




Fig. 6. Phylogenetic tree of the CD41 protein family.

#### 3.3 Chromosome localization of porcine CD41 gene

Chromosomal localization was carried out screening a pig-rodent somatic hybrid cell panel by PCR, using specific porcine CD41 primers (Table1). A specific amplification was observed in 9 (16, 20, 21, 22, 23, 24, 25, 26 and 27) of the 27 hybrid cells (Figure7), which enabled us to localize the porcine *CD41* gene in region p11-2/3p13 of chromosome 12 (*Sscr* 12) with a probability of 0.90 and an error margin lower than 0.1% (Chevalet et al., 1997, www.toulouse.inra.fr/lqc/pcr.htm).

The chromosome localization of the gene was confirmed by screening the INRA Minnesota porcine Radiation Hybrid (IMpRH) panel. The IMpRH mapping tool (Milan et al., 2000; www.imprh.toulouse.inra.fr) revealed that porcine *CD41* gene is closely linked to the SW957 marker (47cM; LOD=9) on the *Sscr* 12, p11-p13 region (Figure8).




Fig. 7. Diagram showing results for the presence/absence of the *CD41* gene in the INRA somatic hybrid cell panel.




Fig. 8. Diagram showing the chromosomal localization of the *CD41* gene using the INRA Minnesota porcine Radiation Hybrid (IMpRH) panel.

#### 3.4 Cell and tissue expression of porcine CD41 transcripts

To investigate the pattern of the porcine *CD41* mRNA expression, RT-PCR analysis was conducted with a variety of pig adult tissues and cell types using VARP1/VARP2 gene-specific primers (Table1). The highest level of CD41 transcripts was detected in platelets, although a moderate level was detected in bone marrow and a low level in ganglions and lungs. No *CD41* transcripts were detected in the rest of tissues and cells analyzed (Figure9).




Fig. 9. RT-PCR expression patterns of *CD51* transcripts in different pig cells and tissues. RU: Relative units. 18S RNA amplification was used as control.

#### 3.5 Cell and tissue expression of porcine CD41 proteins

The precise localization of the *CD41* protein was studied by immunohistochemistry and by flow cytometry with antibodies developed against two different porcine CD41 recombinant proteins.

#### 3.5.1 Expression and purification of porcine recombinant CD41 proteins

Two different cDNA fragments belonging to the functional region of the porcine CD41 protein were amplified and subcloned in the *pET-28b* expression vector. One, 996 bp long and amplified with primers CD41-F2 and CD41-R2 (Table1), contained the coding sequence for amino acids 32 to 363, and the other one, 677 bp long and amplified with primers CD41-F1 and CD41-R1, contained the coding sequence for amino acids 684 to 909, a highly antigenic region selected by the Jameson-Wolf method (Jameson & Wolf, 1988). The recombinant constructions, named respectively *pET-F2R2* and *pET-F1R1*, were transfected and expressed in *E. coli* (DE3). Two different recombinant CD41 proteins were purified: rCD41-F1R1 (about 26 kDa) and rCD41-F2R2 (about 46 kDa) (Figure10).




Fig. 10. Purified CD51 recombinant proteins. A: rCD41-F1R1. B: rCD4-F2R2.

#### 3.5.2 Production of antibodies against porcine rCD41 proteins

An anti-rCD41-F2R2 monoclonal antibody (GE2B6), and two anti-rCD41-F2R2 and antirCD41-F1R1 polyclonal antibodies were produced, and their specific reactivity against the rCD41 proteins tested in immunoblottings. Before being used in immunohistochemical assays, their ability to specifically recognize the platelet CD41 molecules were carried out through immuno precipitations of platelets lysates in non-reduced conditions. An antiporcine CD61 (JM2E5), previously produced by us (Pérez de la Lastra et al., 1997), was used as a positive control. Results are shown in Figure11 in which both polyclonal antibodies, the same as JM2E5, identified two proteins of 110 and 90 kDa, corresponding to the  $\alpha$  and  $\beta$  chains of the receptor  $\alpha_{IIb}\beta_3$ . The antibodies  $\alpha_{IIb}$  specific recognition was demonstrated through an immunoblotting of platelet lysates in non-reducing conditions (Figure12).

www.intechopen.com

126




Fig. 11. Immunoprecipitation results of platelet lysates with anti-rCD41-F1R1 and anti-rCD4-F2R2 in non reducing conditions. JM2E5 anti-CD61 antibody was used as a control (C+).




Fig. 12. Immunoblotting results of anti-rCD41-F2R2 and JM2E5 against a porcine platelet lysate.

#### 3.5.3 Immunohistochemical detection of CD41 proteins

The reactivity of the anti-CD41 monoclonal and polyclonal antibodies was tested by immnohistochemestry on a variety of porcine tissues and cells types. Results are shown in Figures 13 and 14. Immunoreactivity was only detected in the membranes of megakaryocytes from bone marrow. No reactivity was detected in any of the tissues checked, including ganglion, in which a weak CD51 transcription was detected by RT-PCR.






Fig. 13. Immunohistochemistry results with anti-rCD41-F2R2. A: Bone marrow (40X), MK, megakaryocyte. B: Aorta (20X). C: Small intestine (10X). D: Large intestine (10X). E: Uterus (10X).




Fig. 14. Immunohistochemistry results with anti-rCD41-F2R2. A: Spleen (2X). B: Ganglyon (20X). C: Kidney (10X). D: Thymus (10X). E: Tonsil (10X).

#### 3.5.4 Detection of CD41 proteins by flow cytometry

In order to identify the possible PBL cells that express CD41 proteins we carried out a flow cytometry analysis by using both anti-CD41 polyclonal antibodies. Figure15 shows the results in platelets, lymphocytes, granulocytes and erythrocytes with anti-CD41-F2R2. CD41 proteins were only detected in platelets by both polyclonal antibodies.

Furthermore, to test the platelet porcine specificity of the antibodies produced in this study we test their reactivity with platelets from pigs, humans, dogs, horses, goats, chats, sheep and cows by flow cytometry. Both anti-CD41-F2R2 and anti-CD41-F1R1only reacted with porcine platelets (Figure 16), confirming the porcine CD41 specificity of both antibodies.




Fig. 15. Flow cytometry with anti-rCD41-F2R2 detecting expression in blood cells.




Fig. 16. Flow cytometry with anti-rCD41-F2R2 showing no CD41 expression in platelets from different mammals.

#### 3.6 Effect of the platelet activation on the expression of porcine CD41

Previous results obtained in our lab using a two dimension differential in gel electrophoresis (2D-DIGE) technique had shown that the proteome of thrombin activated porcine platelets showed a reduced number of proteins affected in their expression level, among which CD41 was not found. Although CD41 is strongly expressed in platelets, the membrane proteins are usually poorly represented in the gels as a consequence of their high hydrophobicity. As we had produced specific anti-CD41 polyclonal antibodies, we used the anti-rCD41-F2R2 to check, using immunoblotting, if CD41 was or not present in a similar gel than that used in our previous study. Results are shown in Figure 17 in which CD41 integrin was clearly detected.

In order to test if the *CD41* transcripts level was or not modified in the platelets after activation by thrombin, we carried out a real time quantitative PCR (rt-q-PCR) with RNAs from unstimulated and stimulated platelets. Results are shown in Figure18 in which a higher but not significant change in the *CD41* transcripts level was detected after the activation by thrombin (the significant value is 1.5). Three replicates were assayed with very similar results.




Fig. 17. A: Two dimension gel electrophoresis showing the platelet proteome stained with Comassie blue. B: Immunoblotting of platelet proteome with anti-rCD41-F2R2. Red circle shows detection of CD41 protein.




Fig. 18. Real time quantification of CD51 transcripts in unstimulated and thrombin stimulated platelets. R: Ratio (relative abundance to  $\beta$ -actin mRNA). Results represent the average of three replicates.

#### 4. Discussion

In general, the study of genes expressed in platelets is difficult since platelets are enucleated cells that show a reduced level of protein synthesis, and megakaryocytes, the platelets precursors, represent only 0.1% of bone marrow cells (Bray et al., 1987). Nevertheless, in the present study we describe for first time the cloning and characterization of the full-length cDNA for the porcine CD41 ( $\alpha_{IIb}$ ) integrin chain.

The porcine CD41 proteins share common structural elements, including cytoplasmic, transmembrane and extracellular domains and the position of the proteolytic cleavage sites with the CD41 protein of other species. The porcine CD41 integrin showed an average of 75% amino acid identity with their mammal orthologous molecules, being the conservation in the transmembrane and cytoplasmic regions higher than in the extracellular one in all the

species compared. The phylogenetic tree of CD41 family of proteins showed that the closest to porcine CD41 were those of cows and horses, and that the clusters of domestic mammals showed the less divergence in evolution. However, compared with other  $\alpha$  mammal integrins, like  $\alpha_v$  which show 90% of identity (Yubero et al., 2011),  $\alpha_{IIb}$  integrins show lower level of conservation, which could be associated with the number of  $\beta$  chains with which they can form receptors: only one ( $\beta_3$ ) for  $\alpha_{IIb}$ , and at least five for  $\alpha_v$ .

Porcine CD41 conserves all the main structural characteristics that define their functions in other species. The extracellular domain shows that porcine CD41 belongs to  $\alpha$  integrins lacking I domain, a domain present in the NH<sub>2</sub> extreme of some integrins, like  $\alpha_1$ ,  $\alpha_2$  or  $\beta_2$ . which contains the functional sites to bind to ligands (Dickeson & Santoro, 1998; Humphries, 2000). Porcine and human  $\alpha_{\text{IIb}}$ , the same as  $\alpha_{v}$ ,  $\alpha_{5}$  and  $\alpha_{8}$  ones, spreads the ligand binding sites among the first 334 NH<sub>2</sub> amino acid residues (Loftus et al., 1996). One characteristic of the  $\alpha$  integrins lacking I domain is the presence of the seven FG-GAP tandem repeat sequences (W1 to W7; see Figures 3 and 4). Each FG-GAP sequence determines four antiparallel  $\beta$  chains, and the folding of all the seven FG-GAP sequences establishes the globular structure of the integrin, which contains the ligand binding sites. Fibrinogen is the main ligand for  $\alpha_{IIb}\beta_3$  complex. In humans, the binding of fibrinogen to  $\alpha_{IIb}\beta_3$  receptor requires the  $\alpha_{IIb}$  chain Ala<sub>294</sub> to Met<sub>314</sub> residues, which are located in the third FG-GAP repeat (D'Souza et al., 1990). Other experiments, including molecular characterization of the Glanzmann thrombasthenia and mutagenesis analysis, have shown that residues Ala<sub>145</sub>, Asp<sub>163</sub>, Leu<sub>183</sub>, Glu<sub>184</sub>, Tyr<sub>189</sub>, Tyr<sub>190</sub>, Phe<sub>191</sub> and Asp<sub>224</sub> of the  $\alpha_{IIb}$  chain, are also critics for the fibrinogen binding (Grimaldi et al., 1998; Honda et al., 1998; Tozer et al., 1999). The comparison between human and porcine  $\alpha_{IIb}$  integrin sequences showed that all these critic residues are conserved in the porcine molecule.

On the other hand, the fibrinogen only binds to the activated  $\alpha_{IIb}\beta_3$  integrins, this activation being mediated by Ca<sup>++</sup> (Bennett & Vilaire, 1979). The molecular characterization of  $\alpha_{IIb}$ carried out in this study showed that all the four Ca<sup>++</sup> binding domains (consensus sequence DX[D/N]XDGXXD) were also highly conserved in the porcine  $\alpha_{IIb}$  integrin when compared to that in humans.

The transmembrane region of the porcine  $\alpha_{IIb}$  integrin is also highly conserved when compared to their homologous mammalian (80-84% of identity). The sequence GXXXG in this region is essential for a high affinity association of the transmembrane helixes (Senes et al., 2000). Changes as AXXXG or SXXXG in this sequence reduce significantly the affinity between them (Mendrola et al., 2002; Schneider & Engelman, 2004). Our results showed that the same GVLGG sequence was conserved in the  $\alpha_{IIb}$  integrins from all the mammalian species compared, including that of the pig. It has been suggested and supported a "push-pull" mechanism for  $\alpha_{IIb}\beta_3$  regulation in which the destabilization of the hetrodimeric  $\alpha_{IIb}$  and  $\beta_3$  transmembrane interactions push  $\alpha_{IIb}\beta_3$  to its activated state, whereas processes that favor their homomeric association pull  $\alpha_{IIb}\beta_3$  toward its active conformation (Li et al., 2005; Yin et al., 2006). This is in concordance with the high conservation of the GVLGG sequence in the transmembrane region of the porcine (and other mammal)  $\alpha_{IIb}$  chains, since fibrinogen binding to  $\alpha_{IIb}\beta_3$  is a prerequisite for platelets aggregation (Bennett, 2005). It is worthy to note that the porcine  $\alpha_v$  integrin, also present in platelets membranes, contains an AVLGG sequence in the transmembrane region, as well as in all their mammalian homologous with which it was compared (Yubero et al, 2011).

The cytoplasmic region of the porcine  $\alpha_{IIb}$  integrin is also highly conserved (80-89% of identity when compared to their homologous mammalians). A short GFFKR motif, which was involved in the activation of the integrin receptors, is present in the cytoplasmic region of all the human  $\alpha$  integrins. In humans, mutations in the GFFKR motif of the  $\alpha_{IIb}\beta_2$  integrin receptor induce a permanent activation of the integrins. As expected, in all the species compared in this study, the porcine  $\alpha_{IIb}$  integrin contains this motif near to the transmembrane region. The porcine  $\alpha_{IIb}$  integrin also contains in the cytoplasmic region the PPLEE motif, present in all the mammalian  $\alpha_{IIb}$  integrin compared in this study, whose modifications determine changes that interfere with the specific recognizing of the ligands (Filardo & Cheresh, 1994).

Once the porcine  $\alpha_{IIb}$  integrin was characterized, we used a porcine radiation hybrid panel and a somatic cell hybrid panel to map the pig *CD41* ( $\alpha_{IIb}$ ) gene into swine chromosome 12 (*Sscr 12*), region p11(2/3)-p13. This chromosomal localization is in total concordance with heterologous painting data that demonstrate the correspondence between the swine *Sscr* 12 and the human *Hsap* 17 chromosomes (Rettenberger et al., 1995), where *CD41* ( $\alpha_{IIb}$ ) gene maps in the human *Hsap* 17 q21 region (Bray et al., 1987), homologous to the porcine *Sscr* 12 p11-p13 one (Figure 19).




Fig. 19. Chromosomal localization of porcine and human *CD41* genes showing the correspondence between porcine *Sscr* 12 and human *Hsap* 17 chromosomes.

It is interesting to note that the swine *CD41* ( $\alpha_{IIb}$ ) and *CD61* ( $\beta_3$ ) genes are closely located - which confirms our previous results (Morera et al., 2002)-, the same as in humans, where both genes map together in chromosome 17, q21 region (Thornton & Poncz, 1999). This is exceptional for genes coding for  $\alpha$  and  $\beta$  integrins belonging to the same receptor, and it must have a functional significance, as both genes are simultaneously expressed in human megakaryocytes (Bennett et al, 1983). Therefore, the chromosomal assignment of pig  $CD41(\alpha_{IIb})$  gene provides additional evidence of the conserved linkage homology in these chromosome regions among pigs and humans.

We also checked in this study the porcine  $\alpha_{IIb}$  expression profile in different cells and tissues. When we used RT-PCR to detect the  $\alpha_{IIb}$  transcripts level, we observed, as expected, a strong expression in platelets and in bone marrow. However, we also detected a lower expression in lymphatic ganglion and lung, which we explain by the probable

134

presence of platelets or blood cells in them. When we used immnunohistochemisty and flow cytometry to locate accurately the CD41 ( $\alpha_{IIb}$ ) protein expression with specific antibodies produced by us, we confirmed that the presence of CD41 proteins was restricted to platelets and megakaryocytic membranes. The same restricted expression pattern of  $\alpha_{IIb}$  proteins have been detected in other species, like humans and mice, although some studies suggest that  $\alpha_{IIb}$  could be a differentiation marker expressed in early stages of the cellular hematopoietic differentiation (Mitjavila-García et al., 2002) or to be over expressed in tumor cells (Raso et al., 2004). In fact, the  $\alpha_{IIb}/\beta_3$  integrin expression in tumor cells has been controversial as  $\alpha_{IIB}$  and  $\alpha_v$  integrin have similar structures, and although the role of the CD51 integrin in tumor metastasis and angiogenesis is well documented (Chen, 1992, 1997; Mitjans et al., 2000), these studies have been carried out using antibodies that could cross react with the  $\alpha_v/\beta_3$  receptor (Chen et al., 1992; Chen 2006). However, some studies have revealed that the  $\alpha_{II\beta}/\beta_2$  receptor mediates interactions between platelets and tumor cells, detecting an over expression in the filopodia emitted by the platelets in the focal adhesion plates, with the filopodia being the first contact sites between tumor cells and platelets (Chopra et al., 1992).

In this sense, it is worthy to note that in our study we have produced the two first specific anti-porcine  $\alpha_{IIb}$  antibodies, whose specificities we have demonstrated by flow cytometry in cross reactions against platelets from humans, dogs, horses, goats, cats, sheep and cows.

Finally, as  $\alpha_{IIb}/\beta_3$  is involved in adhesion and aggregation of platelets after their activation, we checked if the platelet activation was or not associated with changes in the  $\alpha_{IIb}$  transcripts level. Changes in the proteome of platelet activated by thrombin, the strongest platelet activator, was previously studied in our laboratory, detecting some differential modification in only a small number of proteins, among which the CD41integrin was not included, even though a very sensitive two dimension differential in gel electrophoresis (2D-DIGE) technique was used (Esteso et al., 2008). As CD41 is strongly represented in platelets and it plays an essential role in their activation, we took advantage of the specific anti-porcine  $\alpha_{IIb}$  antibodies produced for the studies presented in this chapter to check if CD41 integrin was or not present in the gels used to carry out those studies. Immunoblotting results clearly showed that CD41protein was detected in the platelet proteome, which confirmed our previous results that showed that platelets did not modify their CD41 protein level after thrombin activation. Moreover, although platelets are enucleated cells that lack their nucleus during the megakaryocytic cells cytoplasm fragmentation, it is well established that they conserve ribosomes, mRNAs, as well as the post-translationally modifying protein mechanisms (Dittrich et al., 2005). For this, we used a real time PCR to check if some change was produced in the  $\alpha_{IIb}$  transcripts level as a consequence of the platelet activation by thrombin. Results showed that although a small increase was detected, this was not statistically significant. It is well established that most changes produced after platelets activation involve post-translational modifications that affect the interactions between transmembrane and cytoplasmic domains of  $\alpha$  and  $\beta$  chains (Russ & Engelman, 1999). So, our results support that the changes produced after thrombin platelet activation, which seems to disrupt the helical interface between the integrin *a* and  $\beta$ subunit transmembrane domains, favoring homomeric  $\alpha_{IIb}$  (and  $\beta_3$ ) transmembrane domain interactions in the  $\alpha_{IIb}\beta_3$  receptor (Luo et al., 2004; Li et al., 2005; Partridge et al., 2005; Yin et al., 2006), must be produced by post-translational regulation, without affecting neither the transcript nor the protein level in the  $\alpha_{IIb}$ .

#### 5. Conclusion

Integrins are a family of heterodimeric transmembrane glycoproteins consiting of varying combinations of noncovalently bound  $\alpha$  and  $\beta$  chains that generate several receptors with different expression patterns and ligand binding profiles.  $\alpha_{IIb}\beta_3$  (CD41/CD61) integrin is the most abundant platelet receptor being responsible for the platelet aggregation. Most of the studies with  $\alpha_{IIb}\beta_3$  integrin have been carried out in humans and mice but little is known about the expression of  $\alpha_{IIb}\beta_3$  integrin in porcine tissues, although pig is generally accepted as an optimal experimental model for different areas, as cardiovascular diseases, because of its similarity to humans. We have previously cloned and characterized the porcine gene coding for the  $\beta_3$  (CD61) chain of the  $\alpha_{IIb}\beta_3$  integrin; however, the one coding for  $\alpha_{IIb}$  (CD41) chain -the only  $\alpha$  subunit for the  $\beta_3$  one- remained to be characterized.

We describe in this chapter the molecular cloning, the structural and comparative analysis, and the expression patterns of the porcine gene coding for the  $\alpha_{IIb}$  integrin chain. Additionally, we also describe the chromosomal localization of the gene.

We used a combined strategy of PCR and RACE reactions to obtain a full porcine  $\alpha_{IIb}$  cDNA sequence from platelet RNA. The pig  $\alpha_{IIb}$  cDNA was 3336-pb long and contained an ORF 3111 b long that encodes a pre- $\alpha_{IIb}$  protein composed by 1036 amino acid residues, from which, 961, 26 and 10 belong to the NH2-extracellular, the transmembrane and the cytoplasmic-COOH domains, respectively. The porcine  $\alpha_{IIb}$  shares with  $\alpha_{IIb}$  from other species: identical structure, a high % amino acid identity, common domains ( $\alpha$ -I, Ca<sup>++</sup> binding, MIDAS), N-glycosylation sites, and the seven FG-GAP tandem repeats. However, in relation to other mammalian  $\alpha$  chains, the porcine  $\alpha_{IIb}$  shares lower identities with those homologous in mammals (78% with humans, horses and cows, 78% with dogs, 75% with rabbits, 73% with mice and 71% with rats). A phylogenetic tree identifies cows CD41 as the closest to pigs.

By using both somatic cell hybrid and irradiated cell hybrid panels, we localized the gene coding for the porcine  $\alpha_{IIb}$  integrin in chromosome *Sscr* 12 region p11-(2/3 p13), in the same region where we previously localized the porcine  $\beta_3$  integrin gene, region that corresponds to the human homologous *Hsap* 17(q21) in chromosome 17.

As expected, the porcine  $\alpha_{IIb}$  mRNAs were predominantly detected in platelets, but they were also detected in bone marrow and ganglion, in which platelets or megakaryocytes –the platelets precursors- were probably presents. To locate accurately the pattern expression of the  $\alpha_{IIb}$  protein, immunohistochemical, immunocytochemical and flow cytometry analysis were carried out. For this, monoclonal and polyclonal antibodies against porcine recombinant  $\alpha_{IIb}$  integrins ( $r\alpha_{IIb}$ ) were previously produced. Citometry flow analysis determined the antibodies specificity for porcine platelets, being the first antibodies described with this characteristic. Immunohistochemical assays confirmed that the  $\alpha_{IIb}$  expression is restricted to the membranes of megacariocytes present in bone morrow. Flow cytometry analysis of PBC confirmed the  $\alpha_{IIb}$  expression in platelet but not in lymphocytes, erythrocytes or granulocytes.

Finally, we checked by RT-Q-PCR if any change was produced in the level of  $\alpha$ IIb transcripts in thrombin activated platelets, no detecting significant ones. This result, together to previous ones obtained by us, support that no change were produced in neither the transcript nor the protein level of  $\alpha$ IIb, supporting  $\alpha$ <sub>IIb</sub> post-translational changes in the  $\alpha$ <sub>IIb</sub> $\beta$ <sub>3</sub> platelet receptor after thrombin activation.

In conclusion, our results are of particular interest because the pig is an animal model system for a variety of immunological, developmental and pathological studies, and because  $\alpha_{IIb}$  integrin plays an essential role in phenomenons so significant as thrombosis, homeostasis, tumors progression and invasion, and differentiation of cells from the myeloid lineage in the bone marrow.


#### 6. References

- Alam N, Goel HL, Zarif MJ, Butterfield JE, Perkins HM, Sansoucy BG, Sawyer TK & Languino LR, (2007). Theintegrin-growth factor receptor duet. *Journal of Cellular Physiology*, Vol.213, pp. 649–653.
- Arce, C., Moreno, A., Millán, Y., Martín de las Mulas, J. & Llanes, D. (2002). Production and characterization of monoclonal antobodies against dog immunoglobulin isotypes. *Vet. Immunol. Immunopathol.*, Vol.6, No.88(1-2), pp. 31-41.
- Bennett, J.S. & Vilaire, G. (1979). Exposure of platelet fibrinogen receptors by ADP and epinephrine. J. Clin. Invest., Vol.64, pp. 1393-1401.
- Bennett, J. S., Hoxie, J. A., Leitman, S. F., Vilaire, G. & Cines, D. B. (1983). Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. *Proc. Natl. Acad. Sci. USA*, Vol.80, pp. 2417-2421.
- Bennett, J.S. (2005). Structure and function of the platelet integrin alfaIIb/beta3. J. Clin. Invest., Vol.115, pp. 3363-3369.
- Bray, P.F., Rosa, J.P., Johnson, G.I., Shiu, D.T., Cook, R.G., Lau, C., Kan, Y.W., McEver, R.P. & Shuman, M.A. (1987). Platelets glycoprotein IIb. Chromosomal localization and tissue expression. *J. Clin. Invest.*, Vol.80, pp. 1812-1817.
- Chen, Y. P., Djaffar, I., Pidard, D., Steiner, B., Cieutat, A. M., Caen, J. P. & Rosa, J. P. (1992). Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. *Proc. Natl. Acad. Sci. USA*, Vol.89, pp. 10169-10173.
- Chen, Y. Q., Trikha, M., Gao, X., Bazaz, R., Porter, A. T., Timar, J. & Honn, K. V. (1997). Ectopic expression of platelet integrin alphaIIb beta3 in tumor cells from various species and histological origin. *Int. J. Cancer*, Vol.72, pp. 642-648.
- Chen, X. (2006). Multimodality imaging of tumor integrin alphavbeta3 expression. *Mini Rev Med Chem* Vol.6, pp. 227-234.
- Chevalet, C., Gouzy, J. & SanCristobal-Gaudy, M. (1997). Regional assignment of genetic markers using a somatic cell hybrid panel: a WWW interactive program available for the pig genome. *Comput. Appl. Biosci.*, Vol.13, pp. 69-73.
- Chopra, H., Timar, J., Rong, X., Grossi, I. M., Hatfield, J. S., Fligiel, S. E., Finch, C. A., Taylor, J. D. & Honn, K. V. (1992). Is there a role for the tumor cell integrin alpha IIb beta 3 and cytoskeleton in tumor cell-platelet interaction? *Clin. Exp. Metastasis*, Vol.10, pp. 125-137.
- Clark. E. A. &Brugge J. S. (1995). Integrins and signal transduction pathways: the road taken. *Science*, Vol. 268, pp.233-239.
- Corbel, C. & Salaun, J. (2002). AlphaIIb integrin expression during development of the murine hemopoietic system. *Dev. Biol.,* Vol.243, pp. 301-311.
- Dickeson, S. K., & Santoro, S. A. (1998). Ligand recognition by the I domain-containing integrins. *Cell Mol. Life Sci.*, Vol.54, pp. 556-566.
- Dittrich, M., Birschmann I, StuhlfelderC, SickmannA, Herterich S, Nieswandt B, Walter U. & Dandekar T. (2005). Understanding platelets. *Thromb. Haemost.*, Vol.94, pp. 916–25.

- D'Souza, S. E., Ginsberg, M. H., Burke, T. A. & Plow, E. F. (1990). The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its alpha subunit. *J. Biol. Chem.*, Vol.265, pp. 3440-3446.
- Edgar, R.C.(2004). MUSCLE: a multiple sequence alignment method with reduced time and and space complexity. *BMC Bioinformatics*, Vol.19, pp. 5, 113.
- Esteso, G., Mora, M.I., Garrido; J.J., Corrales, F. & Moreno, A. (2008). Proteomic analysis of the porcine platelet proteome and alterations induced by thrombin activation. *Journal of Proteomics*, Vol.71, pp. 547-560.
- Filardo, E.J. & Cheresh, D.A. (1994). A  $\beta$  turn in the cytoplasmic tail of the integrin  $\alpha v$  subunit influences conformation and ligand binding of  $\alpha v\beta 3$ . *J. Biol Chem.*, Vol.269, pp. 4641-4647.
- García A, Prabhakar S, Brock C, Pearce A, Dwek R, Watson S., Hebestreit H, & Zitzmann N. (2004). Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. *Proteomics*, Vol.4, pp. 656–68.
- Grimaldi, C.M., Chen, F., Wu, C., Weis, H.J., Coller, B.S. & French, D.L. (1998). Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIb. *Blood*, Vol.91, pp. 1562-1571.
- Hawken, R. J., Murtaugh, J., Flickinger, G. H., Yerle, M., Robic, A., Milan, D., Gellin, J., Beattie, C. W., Schook, L. B. & Alexander, L. J. (1999). A first-generation porcine whole-genome radiation hybrid map. *Mamm. Genome*, Vol.10, pp. 824-830.
- Hemler, M.E., Weitzman, J.B., Pasqualini, R., Kawaguchi, S., Kassner, P.D., & Berditchevsky, F.B. (1994). Structure, biochemical properties, and biological functions of integrin cytoplasmic domains. In Integrins: The Biological Problems. Y. Takada, editor. CRC Press, Boca Raton, Fl, pp. 1-35.
- Honda, S., Tomiyama, Y., Shiraga, M., Tadokoro, S., Takamatsu, J., Saito, H., Kurata, Y. & Matsuzawa, Y. (1998). A two-amino acid insertion in the Cys146- Cys167 loop of the alphaIIb subunit is associated with a variant of Glanzmann thrombasthenia. Critical role of Asp163 in ligand binding. J. Clin. Invest., Vol.102, pp. 1183-1192.
- Humphries, M. J. (2000). Integrin structure. Biochem. Soc. Trans., Vol.28, pp. 311-339.
- Hynes, R.O., 1987. Integrins: a family of cell surface receptors. Cell, Vol.48, pp. 549-554.
- Hynes, R. O. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. *Cell*, Vol.69, pp. 11-25.
- Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. *Cell*, Vol.110, pp. 673-687.
- Hynes, R.O., Lively, J.C., McCarty, J.H., Taverna, D., Xiao, Q. & Hodivala-Dilke, K. (2002). The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb. Symp. Quant. Biol., Vol.67, pp. 143-153.
- Isenberg, G. (1991). Actin binding proteins lipid interactions. *Journal of Muscle Research and Cell Motility*. Vol.12, pp. 136-144.
- Jameson, B. A. & Wolf, H. (1988). The antigenic index: a novel algorithm for predicting antigenic determinants. *Comput. Appl. Biosc.,i* Vol.4, pp. 181-186.
- Jiménez-Marín, A., Garrido, J.J, De Andrés, D.F., Morera, L., LLanes, D. & Barbancho, M. (2000). Molecular cloning and characterization of the pig homologue to human CD29, the integrin  $\beta_1$  subunit. *Transplantation*, Vol.70, No.4, pp.649-655.
- Jiménez-Marin, A., Yubero, N., Esteso, G., Moreno, A., de Las Mulas, J. M., Morera, L., Llanes, D., Barbancho, M. & Garrido, J. J. (2008). Molecular characterization and expression analysis of the gene coding for the porcine beta(3) integrin subunit (CD61). *Gene*, Vol.408, pp. 9-17.

- Li, W., Metcalf, D. G., Gorelik, R., Li, R. H., Mitra, N., Nanda, V., Law, P. B., Lear, J. D., DeGrado, W. F., and Bennett, J. S. (2005). A Push-Pul mechanism for integrin function. *Proc. Natl. Acad. Sci. U SA*, Vol.102, pp. 1424–1429.
- Loftus, J. C., Halloran, C. E., Ginsberg, M. H., Feigen, L. P., Zablocki, J. A. & Smith, J. W. (1996). The amino-terminal one-third of alpha IIb defines the ligand recognition specificity of integrin alpha IIb beta 3. *J. Biol. Chem.*, Vol.271, 2033-2039.
- Lunney, J.K., 2007. Advances in swine biomedical model genomics. Int. J. Biol. Sci., Vol.3, No.3, pp. 179-184.
- Luo, B.H., Springer, T.A. & Takagi, J. (2004) A specific interface between integrin transmembrane helices and affinity for ligand. *PLoS Biol.*, Vol.2, e153.
- Mendrola, J.M., Beger, M.B., King, M.C. & Lemmon (2002). The single transmembrane domains of ErbB receptors self-associate in cell membranes. *J. Biol. Chem.*, Vol.277, pp. 4704-4712.
- Mitjans, F., Meyer, T., Fittschen, C., Goodman, S., Jonczyk, A., Marshall, J.F., Reyes, G. & Piulats, J. (2000). In vivo therapy of malignant melanoma by means of antagonists of alfav integrins. *Int. J. Cancer* Vol.87, pp. 716-723.
- Misdorp, W. (2003). Congenital and hereditary tumors in domestic animals, 2. Pigs: a review. *Vet. Q.*, Vol.25, pp. 17-30.
- Mitjavila-Garcia, M. T., Cailleret, M., Godin, I., Nogueira, M. M., Cohen-Solal, K., Schiavon, V., Lecluse, Y., Le Pesteur, F., Lagrue, A. H. & Vainchenker, W. (2002). Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. *Development*, Vol.129, pp. 2003-2013.
- Morera, L., Jiménez-Marín, A., Yerle, M., Llanes, D., Barbancho, M. & Garrido, J.J. (2002). A polymorphic microsatelite located on pig chromosome band 12p11-2/3p13, within the 3'-UTR of the ITGB3 gene. *Animal Genetics*, Vol.33, pp. 239-240.
- Ody, C., Vaigot, P., Quere, P., Imhof, B. A. & Corbel, C. (1999). Glycoprotein IIb-IIIa is expressed on avian multilineage hematopoietic progenitor cells. *Blood*, Vol.93, pp. 2898-2906.
- Partridge, A.W., Liu, S., Kim, S., Bowie, J.U. & Ginsberg, M.H. (2005). Transmembrane domain helix packing stabilizes integrin *a*IIbβ3 in the low affinity state. *J. Biol. Chem.*, Vol.280, pp. 7294–7300.
- Pérez de la Lastra, J.M., Moreno, A., Pérez, J., Llanes, D. (1997). Characterization of the porcine homologe to human platelet glycoprotein IIb-IIIa (CD41/CD61) by a monoclonal antibody. *Tissue Antigens*, Vol.49, pp. 588-594.
- Raso, E., Dome, B., Somlai, B., Zacharek, A., Hagman, W., Honn, K.V. & Timar, J. (2004). Molecular identification, localization and function of platelet-type 12 lipoxygenase in human melanoma progression, under experimental and clinical conditions. *Melanoma Res.*, Vol.14, pp. 245-250.
- Rettenberger, G., Klett, C., Zechner, U., Kunz, J., Vogel, W. & Hameister, H. (1995). Visualization of the conservation of synteny between humans and pigs by heterologous chromosomal painting. *Genomics*, Vol.26, pp. 372-378.
- Rojiani, M.V., Finlay, B.B., Gray, V. & Dedhar. S. (1991). In vitro interaction of a polypeptide homologous to the human Ro/SS-A antigen (calreticulin) with a highly conserved amino acid sequence in the cytoplasmic domain of integrin alpha subunits. *Biochemistry*, Vol.30, pp. 9859-9866.
- Russ, W.P. & Engelman, D.M. (1999). TOXCAT: a measure of transmembrane helix association in a biological membrane. *Proc. Natl. Acad. Sci. USA*, Vol.96, pp. 863-868.

- Schneider, D. & Engelman, D. M. (2004). Involvement of transmembrane domain interactions in signal transduction by alpha/beta integrins. J. Biol. Chem., Vol.279, pp. 9840-9846.
- Senes, A., Gerstein, M. & Engelman, D. M. (2000). Statistical analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions. J. Mol. Biol., Vol.296, pp. 921-936.
- Springer, T. A. (1997). Folding of the N-terminal, ligand-binding region of integrin alphasubunits into a beta-propeller domain. *Proc. Natl. Acad. Sci. USA*, Vol.94, pp. 65-72.
- Schwartz. M. A., Schaller. M. D. & Ginsberg. M. H. (1995). Integrins. Emerging paradigms of signal transduction. Annu. Rev. Cell Dev. Biol., Vol.11, pp. 549-599.
- Takada, Y., Elices, M. J., Crouse, C. and Hemler, M. E. (1989). The primary structure of the alpha 4 subunit of VLA-4: homology to other integrins and a possible cell-cell adhesion function. *Embo J.*, Vol.8, pp. 1361-1368.
- Thornton, M. A. & Poncz, M. (1999). Characterization of the murine platelet alphaIIb gene and encoded cDNA. *Blood*, Vol.94, pp. 3947-3950.
- Tozer, E.C., Baker, E.K., Ginsberg, M.H. & Loftus, J.C. (1999). A mutation in the alfa subunit of the platelet integrin alphaIIbeta3 identifies a novel region important for ligand binding. *Blood*, Vol.93, pp. 918-924.
- Wall, C. D., Conley, P. B., Armendariz-Borunda, J., Sudarshan, C., Wagner, J. E., Raghow, R. & Jennings, L. K. (1997). Expression of alpha IIb beta 3 integrin (GPIIb-IIIa) in myeloid cell lines and normal CD34+/CD33+ bone marrow cells. *Blood Cells Mol. Dis.*, Vol.23, pp. 361-376.
- Weiss, E. J., Bray, P. F., Tayback, M., Schulman, S. P., Kickler, T. S., Becker, L. C., Weiss, J. L., Gerstenblith, G. & Goldschmidt-Clermont, P. J. (1996). A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. *N. Engl. J. Med.*, Vol.334, pp. 1090-1094.
- Xiong, J.P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D.L., Joachimiak, A., Goodman, S.L., Amin, M. & Arnaout, M.A. (2001). Crystal structure of the extracellular segment of integrin alphaV beta3. *Science*, Vol.294, pp. 339-345.
- Yamada, K.M., 1991. Adhesive recognition sequences. J. Biol. Chem., Vol.266, pp. 12809-12812.
- Yerle, M., Echard, G., Robic, A., Mairal, A., Dubut-Fontana, C., Riquet, J., Pinton, P., Milan, D., Lahbib-Mansais, Y. & Gellin, J. (1996). A somatic cell hybrid panel for pig regional gene mapping characterized by molecular cytogenetics. *Cytogenet. Cell Genet.*, Vol.73, pp. 194-202.
- Yerle, M., Pinton, P., Robic, A., Alfonso, A., Palvadeau, Y., Delcros, C., Hawken, R., Alexander, L., Beattie, C., Schook, L., et al. (1998). Construction of a whole-genome radiation hybrid panel for high-resolution gene mapping in pigs. Cytogenet Cell Genet., Vol.82, pp. 182-188.
- Yin, H., Litvinov, R.I., Vilaire, G., Zhu, H., Li, W., Caputo, G.A., Moore, D.T., Lear, J.D., Weisel, J.W., DeGrado, W.F. & Bennett, J.S. (2006). Activation of platelet allbb3 by an exogenous peptide corresponding to the transmembrane domain of allb. *J. Mol. Chem.*, Vol.281, No.48, pp. 36732–36741.
- Yubero, N., Jiménez-Marín, Á., Barbancho, M., & Garrido, J.J. (2011). Two cDNAs coding for the porcine CD51 (α<sub>v</sub>) integrin subunit: cloning, expression analysis, adhesion assays and chromosomal localization. *Gene*, Vol.481, pp. 29-40.



Molecular Cloning - Selected Applications in Medicine and Biology Edited by Prof. Gregory Brown

ISBN 978-953-307-398-9 Hard cover, 324 pages **Publisher** InTech **Published online** 12, October, 2011 **Published in print edition** October, 2011

The development of molecular cloning technology in the early 1970s created a revolution in the biological and biomedical sciences that extends to this day. The contributions in this book provide the reader with a perspective on how pervasive the applications of molecular cloning have become. The contributions are organized in sections based on application, and range from cancer biology and immunology to plant and evolutionary biology. The chapters also cover a wide range of technical approaches, such as positional cloning and cutting edge tools for recombinant protein expression. This book should appeal to many researchers, who should find its information useful for advancing their fields.

#### How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Gloria Esteso, Angeles Jiménez-Marîn, Gema Sanz, Juan José Garrido and Manuel Barbancho (2011). Molecular Cloning, Characterization, Expression Analysis and Chromosomal Localization of the Gene Coding for the Porcine αIIb Subunit of the αIIbβ3 Integrin Platelet Receptor, Molecular Cloning - Selected Applications in Medicine and Biology, Prof. Gregory Brown (Ed.), ISBN: 978-953-307-398-9, InTech, Available from: http://www.intechopen.com/books/molecular-cloning-selected-applications-in-medicine-and-biology/molecularcloning-characterization-expression-analysis-and-chromosomal-localization-of-the-gene-codi



#### InTech Europe

University Campus STeP Ri Slavka Krautzeka 83/A 51000 Rijeka, Croatia Phone: +385 (51) 770 447 Fax: +385 (51) 686 166 www.intechopen.com

#### InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai No.65, Yan An Road (West), Shanghai, 200040, China 中国上海市延安西路65号上海国际贵都大饭店办公楼405单元 Phone: +86-21-62489820 Fax: +86-21-62489821 © 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the <u>Creative Commons Attribution 3.0</u> <u>License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

# IntechOpen

## IntechOpen